Unlocking the Secrets of Cancer Stem Cells with γ-Secretase Inhibitors: A Novel Anticancer Strategy

Maryam Ghanbari-Movahed, Zahra Ghanbari-Movahed, Saeideh Momtaz, Kaitlyn L. Kilpatrick, Mohammad Hosein Farzaei, and Anupam Bishayee

Abstract: The dysregulation of Notch signaling is associated with a wide variety of different human cancers. Notch signaling activation mostly relies on the activity of the γ-secretase enzyme that cleaves the Notch receptors and releases the active intracellular domain. It is well-documented that γ-secretase inhibitors (GSIs) block the Notch activity, mainly by inhibiting the oncogenic activity of this pathway. To date, several GSIs have been introduced clinically for the treatment of various diseases, such as Alzheimer’s disease and various cancers, and their impacts on Notch inhibition have been found to be promising. Therefore, GSIs are of great interest for cancer therapy. The objective of this review is to provide a systematic review of in vitro and in vivo studies for investigating the effect of GSIs on various cancer stem cells (CSCs), mainly by modulation of the Notch signaling pathway. Various scholarly electronic databases were searched and relevant studies published in the English language were collected up to February 2020. Herein, we conclude that GSIs can be potential candidates for CSC-targeting therapy. The outcome of our study also indicates that GSIs in combination with anticancer drugs have a greater inhibitory effect on CSCs.

Keywords: cancer stem cells; γ-secretase; γ-secretase inhibitors; Notch signaling; cancer treatment

1. Introduction

Despite the remarkable progress being made in cancer treatment, cancer is the leading cause of death worldwide. There is evidence that a rare subset of cancer cells are responsible for resistance to therapy and holding stemness functions/properties, which are known as cancer stem cells (CSCs). Therefore, these cell subpopulations induce tumor perpetuation, even after effective therapies, and result in aggression of the tumor. The CSC theory of cancer progression proposes that a tumor is a hierarchically organized tissue with CSCs at the top position in the hierarchy, which produces more differentiated cancer cells with a reduced or restricted potential of proliferation. In recent years, the CSC theory has been subjected to increasing attention and excitement, with researchers believing this theory would augment our knowledge about the molecular and cellular events within tumor progression, contributing to metastasis, recurrence, and resistance to therapy [1].
CSCs possess similar stemness properties to normal stem cells, including the differentiation, proliferation, and self-renewal capabilities that create heterogeneous cancer cell populations. Considering these similarities, normal stem cells and CSCs are usually characterized by the cell surface markers, such as CD20, CD90, CD133, CD44, and CD166 [2]. These markers are used to isolate CSCs by magnetic-activated cell sorting or fluorescence-activated cell sorting techniques [3,4]. Additionally, there are various functional assays for the isolation of CSCs, such as side population cells, tumorigenicity, immune selection by natural killer cells, the aldehyde dehydrogenases (ALDH) assay, and label-retaining methods [3]. Moreover, their tumor-forming capacity is characterized by their increased tumor-repopulating ability when transplanted into immunodeficient mouse models. Additionally, sphere formation assays, as in vitro assays, are used for the enrichment and identification of CSCs [5].

To date, numerous cellular signaling pathways and mediators have been identified, which are potentially able to mediate the carcinogenesis process. The Notch pathway is a highly conserved signaling pathway that plays a critical role in proliferation, development, maintenance of stem cell and multicellular organism homeostasis, differentiation, and specification of cell fate [6]. The Notch signaling pathway also contributes to connections between the self-renewal ability of CSCs and angiogenesis and is therefore gaining attention for targeting CSCs [7]. Notch signaling activation mostly relies on the activity of the γ-secretase enzyme that cleaves the Notch receptors and releases the active intracellular domain. Therefore, γ-secretase inhibitors (GSIs) are promising therapeutic targets for the suppression of Notch signaling. GSIs were the first class of compounds to reach clinical development in cancer research and can be divided into three classes, namely, sulfonamides, azepines, and peptide isosteres, of which sulfonamides and azepines are more commonly used [8]. Several studies have shown that these inhibitors possess anticancer, anti-CSC, antiangiogenesis, and antitumor growth activities and can cause apoptosis, especially in combination with targeted chemotherapeutic drugs. Therefore, the blockade of Notch signaling by GSIs might be a promising target for cancer therapy through the complete eradication of CSCs [9]. Despite the availability of GSIs, Notch-related treatments are presently prohibited by side effects, because of the requirement for the Notch pathway in most tissues [10]. Using nano-delivery systems for CSC-targeted therapy is one of the strategies for overcoming these challenges [11].

Although a few reports present an overview of GSIs, these publications evaluate the antitumor activities of GSIs in a limited number of cancers or review the pharmacological activities of GSIs without a particular emphasis on their anticancer effects [12–14]. Moreover, a comprehensive and critical systematic review on the effect of GSIs on CSC elimination within different cancers has not been conducted in the past. Therefore, the present systematic review was conducted to critically evaluate the results obtained from studies on the effect of GSIs on the elimination of a wide variety of CSCs.

2. The Role of the Notch Signaling Pathway in Cancer

Notch signaling starts with Notch receptors binding to ligands of the Delta-like ligand (Dll) and Jagged families, leading to successive cleavages, first in the extracellular domain, and then in the transmembrane domain, which release the intracellular domain of Notch (ICN) and allow its translocation to the nucleus. In the nucleus, ICN enhances the expression of downstream targets such as the Hairy/Enhancer of Split (HES) gene via binding the transcription factor CSL (CBF1, suppressor of hairless and LAG1), and mastermind-like polypeptides (MAML) [15].

One of the primary connections between cancer and Notch signaling was found in 1991 in human T-cell acute lymphoblastic leukemia [16]. In B-cell malignancies, such as chronic lymphocytic leukemia, Notch-1 mutations were associated with an enhanced progression of disease and chemotherapy resistance [17]. In addition to the dysfunction of Notch receptors in leukemia, the ligand Jagged-2 is considerably overexpressed in multiple myeloma (Figure 1) [18].
Figure 1. Molecular mechanisms underlying the anticancer properties of GSIs. First, the Notch receptor interacts with the Notch ligand, such as DLL, and initiates proteolytic cleavage at the extracellular site, followed by cleavage at the intracellular site by γ-secretase, leading to the release of NICD. Then, NICD is translocated into the nucleus, where it interacts with CSL and MAML to form a transcription-activating complex. GSIs can inhibit these steps, including receptor/ligand binding, the release of NICD, and the interaction of NICD and downstream targets, as well as NICD protein stability, and can thus have anticancer effects. Abbreviations: CSL, CBF1, suppressor of hairless and LAG1; DLL, Delta-like ligand; EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; GSIs, γ-secretase inhibitors; HER2, human epidermal growth factor receptor 2; HIF1α, hypoxia-inducible factor 1α; MAML, mastermind-like; NF-κB, nuclear factor-kB; NICD, Notch intracellular domain; PI3K, phosphatidylinositol-3-kinase; PTEN, phosphatase and tensin homolog.

The oncogenic reach of the Notch pathway is partially due to its crosstalk with other signaling pathways; for example, Hedgehog, Janus kinase (JAK)/signal transducers and activators of transcription (STAT), receptor tyrosine kinases (RTKs), Wnt, and transforming growth factor-β (TGF-β) decapentaplegic pathways. In addition to TGF-β and Wnt, vascular endothelial growth factor (VEGF), phosphatidylinositol 3-kinase (PI3K)/Akt, Ras, nuclear factor-κ-light-chain-enhancer of activated B cells (NF-kB), mammalian target of rapamycin (mTOR), hypoxia-inducible factor (HIF), and interleukin-6 (IL-6) are pertinent
to Notch crosstalk [19]. It has been indicated that NF-κB signaling regulates the Notch pathway and is regulated by the Notch pathway. For instance, the intracellular domains of Notch3 and Notch1 have been observed to stimulate NF-κB signaling components, such as the inhibitor of κB kinase (IKK)) [20]. Indeed, based on evidence of Notch signaling’s role in cancer progression and development, this pathway has become a main target for new therapeutic treatments in this field [21].

3. The Role of GSIs in Notch Signaling Pathway Inhibition

Depending on the chemical structure and binding sites, GSIs can be divided into two large classes, namely peptide inhibitors and non-peptide inhibitors. Peptide inhibitors are divided into five sub-classes, namely peptide aldehyde derivatives, difluoroketone derivatives, hydroxyethylene dipeptide isostere derivatives, α-helical peptide derivatives, and dipeptide analogues. Non-peptide inhibitors represent two sub-classes, namely benzodiazepines derivatives and sulfonamides derivatives [22].

The peptide inhibitors interact well with two aspartates present at the active site, but are not susceptible to cleavage via the action of protease. For example, difluoroketone peptidomimetic inhibitors, such as difluoroketone-167 (DFK-167), can directly bind to the active site. The non-peptide inhibitors, such as LY-411,575, N-[N-(3,5-difluorophenacyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and LY-450,139, bind to docking sites and consist of non-competitive γ-secretase inhibitors. These inhibitors suppress the S3 cleavage of the Notch receptors to block the Notch activity [23].

MK-0752 (cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl] propionic acid), which is a potent GSI with an adequate oral bioavailability, blocks NICD cleavage and its subsequent nuclear translocation [24]. Another GSI, known as RO4929097, which is a dipeptide analogue, has been designed to be used as a chiral building block for the preparation of malonamide derivatives which can act as a GSI [23]. One study showed that RO4929097 could inhibit tumor growth and has on-target pharmacodynamic effects in preclinical models of blood cancer [25]. L-685,458, which belongs to the hydroxyethylamines, contains a hydroxyethylene dipeptide isostere and can function as a transition state analogue mimic of an aspartyl protease. PF-03084014, which belongs to dipeptide analogues, is a selective, noncompetitive, and reversible GSI [23]. One study indicated that PF-03084014 reduced mammosphere formation in vitro, and showed antimitastic and antitumor activity in various breast xenograft models [26]. It was shown that DAPT in combination with taxanes induced cycle arrest in colorectal cancer (CRC) cells [27]. Another study used GSIs such as dibenzazepine (DBZ), L-685,458, and DAPT to examine their impact on the survival or growth of a CRC cell line. Surprisingly, this study could not elicit major CRC cell growth suppression using these GSIs. Nevertheless, treatment with these compounds significantly decreased the Val1744-NICD fragment abundance (a Notch fragment that is greatly detectable in a subset of CRC cell lines) after a few hours. DBZ appeared more effective and persistent. This result showed that GSIs in combination with chemotherapy were more effective than GSIs alone. In the same study, a combination of GSIs and platinum-based therapy, in particular cisplatin, was capable of enhancing the cell death in CRC [28]. Another study revealed that the inhibition of DLL4- and DLL1-mediated Notch signaling led to a loss of intestinal goblet cells, but inducible Jagged-1 deletion had no obvious phenotype [29]. Moreover, it was reported that MRK-003 treatment reduced the tumor onset and tumor burden in BALB/c-neuT female mice bearing ERBB2-positive breast cancer cells [30]. The chemical structures of several GSIs are presented in Figure 2. Despite their different chemical structures, all GSIs that impair Notch signaling act through its suppression [8,31].
Figure 2. Chemical structure of selected \(\gamma\)-secretase inhibitors. Abbreviations: DAPT, (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) and DBZ, dibenzazepine.

4. Methodology for the Literature Search and Study Selection

The current systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [32]. The objective of this review is to provide a systematic review of in vitro and in vivo studies for investigating the impact of GSIs on cancer stem cells. Various electronic scholarly databases, including Scopus, PubMed, Science Direct, Google Scholar, and Web of Science, were searched and relevant studies in English language were collected up to February 2020. The search syntax included “cancer stem cell” OR “tumor stem cell” OR “initiating tumor cell” OR “neoplastic stem cell” OR “colony forming unit” AND “gamma-secretase inhibitor” OR “\(\gamma\)-secretase inhibitor”. The primary search was conducted by two researchers separately, and unrelated
studies were excluded based upon their titles and abstracts. Review articles, meta-analyses, books, book chapters, conference abstracts, case reports, clinical trials, and non-English articles were also excluded. An overview of the literature search and selection process is presented in Figure 3.

Figure 3. Chemical structure of selected γ-secretase inhibitors. Abbreviations: DAPT, (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) and DBZ, dibenzazepine.

5. Anticancer Activities of GSIs against CSCs

Among 118 eligible articles, 64 and 4 studies were performed using in vitro cancer cell lines and in vivo animal models, respectively, and in 50 studies, both in vitro and in vivo models were used. Considering the major aspects of the total included studies and based upon the location of the cancer, the results are presented in the next sections (Tables 1 and 2).

5.1. Adenoid Cystic Carcinoma

A study by Panaccione et al. [33] investigated the anticancer mechanism of GSIs in adenoid cystic carcinoma (ACC) cell lines under both in vitro and in vivo conditions. The in vitro study was performed by treating Accx11 cells with 1–10 μM DAPT with or without
radiation for 24–96 h. For the in vivo assay, mice were treated with 50 mg/kg DAPT for 35 days. The treatment blocked S-phase kinase-associated protein 2 and the Notch 1 intracellular domain (N1-ICD), suppressed the growth of ACC in vivo, reduced CD133* cells and sensitized them to radiation, and led to the induction of cyclin-dependent kinase inhibitor 1B (p27Kip1). Therefore, the combination of radiation and GSI exerted a greater effect on the elimination of CD133* cells compared with either agent alone.

5.2. Blood Cancer

In an experiment, different lymphoma cell lines were exposed to 0.1–100 µM L685458 for 24 h and subjected to a colony-forming unit (CFU) assay. L-685458 potently blocked the CFU and reduced the lymphoma stem cell population [34].

In another study, Ikram et al. (2018) used a three-dimensional (3D) cell culture to assess the antitumor effects of DAPT. The pretreatment of lymphoma cells with DAPT (5 µM) with or without NSC23766 (Rac-specific small-molecule inhibitor) for 24 h showed a significant decrease of the lymphoma stem cell population and an increased sensitivity to doxorubicin [35].

The administration of varying concentrations of DAPT (8–16 µM) for 14 days decreased the colony number in leukemic stem cells, leading to a decline in the size of large colonies by suppressing their proliferation in a concentration-dependent way [36]. Furthermore, another study showed that treatment with MRK-003 (150 mg/kg) eliminated leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-cell acute lymphoblastic leukemia (T-ALL) [37].

In a T-ALL cell line with NOTCH1 mutations (DND-41) and AML cell line (NB4), GSI-XXI (compound E, 10 µM) treatment, alone or in combination with cyclopamine or quercetin for 1–7 days, suppressed the colony formation ability of these cells. The addition of cyclopamine or quercetin to compound E enhanced the inhibitory effect on DND-41 cell line growth and blocked the activation of NOTCH1 in NB4 cell lines [38].

In another study, AA and HEL erythroid leukemia cells were cultured with three GSIs (GSI-IX, 20 µM; GSI-XII, 5 µM; and GSI-XXI, 10 µM) for 1–7 days. The study claimed that treatment with GSIs inhibited the colony formation ability and short-term cell growth, while GSI-XXI treatment enhanced the AA cell line growth [39].

In multiple myeloma cancer stem cells (MM-CSCs), the effect of bruceantin (a quassinoid isolated from Brucea species) was evaluated in the presence of GSI. Bruceantin effectively controlled the MM-CSCs’ viability, migration, proliferation, and angiogenesis. MM-CSC pretreatment with the GSI (RO4929097, 10 µM) and increasing doses of bruceantin for 1 day inhibited the proliferation of these cells [40].

5.3. Brain Cancer

In brain cancer cell lines, it was established that the suppression of Notch signaling with DAPT inhibited hypoxia-induced GSC expansion [41]; abolished the effects of STC1 on N1-ICD production, SOX2 expression, and the sphere-forming capacity [42]; reduced the CSC of CD133+ and inhibited the proliferation of SHG-44 cells [43]; suppressed the transition from CD1331/CD1442 to double-positive (DP) [44]; inhibited cell growth and reduced the sphere formation capacity in glioblastoma neurosphere cultures [45]; and downregulated HIF-1α and hes1, reduced the number of nestin+ cells, increased the number of β-III-tubulin+ cells, and enhanced MKI67 and neuronal differentiation [46]. However, one study showed that DAPT treatment reduced brain CSCs, but had no survival benefit for mice injected with DAPT-treated GBM neurosphere cells [47].

DAPT treatment in combination with radiation [48], gleevec and amph1D peptide [49], D341Med with HBMEC [50], and imatinib [51], resulted in an increase of apoptosis and radio-sensitivity in ihBTC2 cells [48]; the induction of neurosphere dispersion that resulted in cell death [49]; the downregulation of Bmi-1, CDK6, c-Myc, and CCND1 expression in
D341Med, and a reduction in the tumor size and volume [50]; and the effective growth inhibition of GBM cells [51].

The administration of DAPT and INCB3619 downregulated the expression of HES1 and HEY1 Notch target genes in both 0822 and 0308 cell lines. In the 0308 cell line, INCB3619 and DAPT also downregulated the expression of YKL-40/CHI3L1, while the survival was prolonged in mice [52].

In four different studies, DAPT, L685,458, BMS-708163, and RO4929097 treatment led to an increase of the ASCL1 levels in ASCL1\(^\text{hi}\) GSCs and a decrease in sphere-forming cells (SFCs) [53]; inhibited glioma tumor-initiating cell growth in a concentration-dependent manner, suppressed tumor growth, and prolonged the survival rate in vivo [54]; increased radiation-induced apoptosis and decreased the clonogenic survival of GSCs [55]; and decreased the number of CSCs by reducing proliferation and increasing cell death that was associated with decreased levels of STAT3 and Akt phosphorylation and resulted in the inhibition of tumor growth and enhancement of the survival rate [56].

Upon the usage of different concentrations of GSI-18 in vitro and in vivo, two studies reported a reduction in Hes1 protein and mRNA levels in DAOY cells, the suppression of clonogenicity, and the induction of anticancer effects mediated by suppression of the Notch signaling pathway [57], and the induction of a phenotype transformation towards non-tumorigenic cells, along with a decrease in proliferation and increase in differentiation, as well as apoptosis [58].

MRK-003, alone or combined with GSNO or chloroquine, reduced the baseline side population in primary glioma cultures and suppressed the increase of the side population induced by GSNO [59]; prevented neurosphere formation in HCMV-infected GBM cells and reduced the functionality or number of CSCs [60]; decreased the viability and sphere-forming capacity and increased apoptosis through suppression of the Akt pathway [61]; and induced autophagy in glioma neurosphere lines and reduced cell proliferation, cell growth, and the colony formation ability [62].

GSI-I treatment sensitized U251 and U87 cell lines to radiation through the reduction of radio-resistant CD133\(^+\) cells, enhanced the radio-sensitivity in cancer cells, and suppressed the tumor growth [63]. GSI-I also enhanced the therapeutic effect of temozolomide and led to an increase in CD133\(^+\) glioma cytotoxicity [64].

In a study by Pietras et al. [65], MK-003 (10 \(\mu\)M), alone or in combination with tetradecanoyl phorbol acetate, suppressed the glioma primary cells induced by PDGF and eliminated the cancer cells expressing stem cell markers.

In GSCs, RO4929097, either alone or in combination with farnesyltransferase inhibitors, blocked the Akt pathway and inhibited the cell-cycle progression, thus enhancing the radio-sensitivity and reducing the tumor growth. This combination, in addition to radiation, led to a durable response in orthotopic tumor models [66].

Treatment with MK0752 (25 \(\mu\)M) decreased the proliferation and self-renewal ability of GSCs and reduced the number of secondary neurospheres by differentiating GSCs into less proliferative glioma progenitor cells [67].

Another study by Dai et al. [68] investigated the change of glycosylation patterns upon treatment with GSI in GBM CSCs. For this purpose, compound E was cultured with these cancer cells, resulting in a phenotype transformation of CSCs toward a less tumorigenic form upon compound E treatment. Moreover, GSI-II treatment (0.2 \(\mu\)g) for 20 days effectively suppressed the CSC generation in U87 cells and significantly abrogated the proliferation and differentiation of U87 tumor-initiating cells [69].

5.4. Breast Cancer

The outcomes of seven in vitro and in vivo studies on breast cancer cells indicated that suppression of the Notch pathway with DAPT suppressed the activation of Notch by integrin-linked kinase (ILK). ILK knockdown blocked breast CSCs in vitro [70]; reduced the expression of Notch signal effectors NICD, Jagged 1, HES1, and signal peptide CUB EGF-like domain-containing protein 2 (SCUBE2); and decreased the self-renewal ability of breast
CSCs [71]. It also blocked the cleavage of the CD44 intracytoplasmic domain, reduced the mammosphere-forming ability, decreased cell invasion and proliferation of triple-negative breast cancer (TNBC) cells, and suppressed tumor formation in mouse xenograft models [72,73]. These studies also showed that treatment with DAPT decreased the number of mammary progenitor cells and stem cells in p53-deficient mammary epithelium [74], reduced the percentage of CD44hi/CD24low cells, lessened micro- and macro-metastases in mice, and inhibited the colony formation ability of brain metastatic MDA-MB-231 cell lines [75]. Moreover, DAPT treatment led to a significant inhibition of Notch-mediated cell survival and invasion under hypoxia through increasing E-cadherin expression and suppressing the phosphorylation of Akt in breast cancer cells [76].

Five other studies reported that treatment with various concentrations of DAPT, alone or combined with different factors (e.g., radiation, lapatinib, gefitinib, tamoxifen, and 6-shogaol), led to inhibition of the mammosphere-forming ability and an increased TIC gene expression signature, and suppressed the expansion of CD44hi/CD24low TRCs after radiation [77], decreased mammosphere formation and the acini size in DCIS cell lines by inhibiting Notch and ErbB1/2 [78], blocked CSC activity induced by estrogen both in vitro and in vivo, and helped gefitinib to entirely suppress the estrogen effect [79]; inhibited the estrogen receptor-α promoter activity, reduced the tamoxifen sensitivity, and enhanced the expression of markers associated with basal-like breast cancers [80]; and blocked the spheroids and breast cancer cell proliferation and suppressed the colony formation capacity and number of spheroids through inhibiting the Notch pathway [81].

In a study by Mamaeva et al. [82], the anticancer effect of glucose-functionalized nanoparticles carrying DAPT on breast CSCs was assessed. To induce Notch suppression, the mesoporous silica nanoparticles were loaded with the compounds. In vitro, breast CSCs were exposed to variable concentrations of DAPT nanoparticles (5–50 µg/mL) for 24 h, indicating that DAPT treatment reduced the CSC population. In vivo, treatment with DAPT-loaded particles or free DAPT led to a significant decrease in the size of the cancer cell population. As a result, glucose-functionalized mesoporous silica nanoparticles carrying DAPT significantly eliminated the number of CSCs.

GSI-XVII therapy (5 µM, with or without radiation) decreased the self-renewing capacity and prevented the recombinant human erythropoietin-induced enhancement in primary sphere formation [83], while preventing the radiation-induced DLL3, Notch2, Jagged1, and DLL1 gene expression and significantly decreased the number of breast CSCs [84]. It was reported that various concentrations of GSI-I, ranging from 1–10 µM for 24, significantly inhibited breast CSCs [85].

The in vitro and in vivo treatment of different concentrations of MRK-003, either alone or in combination with lapatinib, trastuzumab, and docetaxel, resulted in Notch-1 inhibition, prevented mammosphere formation, inhibited the proliferation of bulk HER2+ HCC1954 cells, and prevented tumor relapse in xenograft models [86], and suppressed Notch signaling activation and decreased the number of CSCs, while a combination of MRK-003 and docetaxel enhanced this activity [87]. MRK-003 was also shown to decrease the viability of cells derived from tumorspheres in vitro, reduce tumor-initiating cells, and block the proliferation and self-renewal ability of mammosphere-resident cells, and induced their apoptosis and differentiation [88].

Two studies using different concentrations of DAPT and compound E with or without AD-01 reported that the treatment inhibited the growth and metastasis of the cancer stem-like cells of 231BrM in the brain through suppressing the expression of HES5 in vitro and in vivo [89]. In addition, the combined treatment of DAPT and compound E with AD-01 led to a reduction in the mammosphere-forming efficiency (MSFE) and enhanced the anti-CSC effects [90].

In another study, mammosphere or monolayer breast cancer cell cultures were treated with DAPT (10 µM), and MCF-7 cells were treated with dibenzazepine (DBZ) (10 µM) for 3 days. DAPT treatment decreased the proportion of ESA+/CD44+/CD24low cells. Both DAPT and DBZ significantly reduced the N1-ICD and decreased the HEY2 and HES1
expression. In an in vivo study, mice were treated with 1 mg/mL DBZ for 3 days. DBZ treatment completely ablated tumor initiation and significantly decreased the size and volume of MCF-7 tumors [91].

The administration of LY-411 and LY-575 (25–50 µM), MRK003 (10–20 µM), and LLNle (0.5 µM) for 1–28 days significantly decreased the mammosphere-forming ability. MRK003 treatment irreversibly inhibited the mammosphere-forming ability, but treatment with either Ly-411,575 or LLNle had a transient effect on mammosphere formation [92].

MK-0752 (25 µM) and RO4929097(10 µM), alone or in combination with tocilizumab, suppressed tumor growth, but enhanced the CSCs in breast cancer cells expressing Notch3, while inducing IL-6. Treatment with MK-0752 led to the induction of IL-6 through Hey2-Notch3 signaling inhibition. Furthermore, hypoxia-inducible factor 1α (HIF1α) downregulated breast CSCs by reducing the IL-6 levels in breast cancer cells expressing Notch3. Using in vivo xenograft models, the concurrent use of tocilizumab and MK-0752 caused a significant reduction in breast CSCs and suppressed tumor growth [93]. Another study also indicated that MK-0752 treatment with or without docetaxel in mice bearing human tumors reduced the primary and secondary mammosphere-forming efficiency (MSFE); decreased the ALDH+ and CD44+/CD24− subpopulations; downregulated NICD, Hes1, Hey1, Hes5, and Myc; and reduced tumor growth. Taken together, GSI treatment decreased breast CSCs and increased the efficacy of docetaxel [31].

The co-culture of CD44+CD24low+ and CD44+CD24neg cells with different GSIs (RO492-0927, 10 µM and DAPT, 5–10 µM) for 1–12 days led to a significant reduction in N1-ICD and decreased the expression of Sox2 and the sphere formation ability. Taken together, the blockade of Notch decreased the Sox2 expression and colony- and sphere-forming capacity. In in vivo nude mice, RO4920927 inhibited tumor growth in CD44+CD24low+ cells [94].

In another investigation, RO4929097 (0.1 nM–10 µM) treatment decreased the expression of Hey1, HeyL, and Hes1 and significantly reduced the colony-forming capacity of SUM149 and SUM190 cells irritated with radiation. In 2D and 3D clonogenic assays, RO4929097 treatment sensitized cell lines to ionizing radiation. The results also demonstrated that treatment with RO4929097 suppressed inflammatory cytokine synthesis, including interleukin (IL-8), IL-6, and tumor necrosis factor-α (TNF-α) [95].

5.5. Colorectal Carcinoma

DAPT treatment (10–20 µmol/L) led to the blockage of Notch signaling and partially suppressed the effect of KRAS on Hes1 in colorectal carcinoma cells. The DAPT treatment also reduced the number of CSCs [96].

In another study, the inhibition of Notch by DAPT significantly reduced the Lgr5-GFP cell population in Lgr5-EGFP-CreER T2 organoids. The suppression of Notch by GSI led to a reduction in Ascl2 levels and also enhanced apoptotic cells shed into the lumen [97]. Furthermore, the suppression of Notch by DAPT decreased the colon cancer stem cell (CCSC) population and enhanced the non-CCSC population. DAPT treatment also inhibited asymmetric division and decreased symmetric CCSC-CCSC division [98].

When utilizing soluble Jagged-1-Fc protein and DAPT in colorectal cancer cells, it was observed that the Notch-1 signaling pathway activates epithelial–mesenchymal transition (EMT)/stemness-associated proteins Slug, Smad-3, and CD44 by inducing the expression of Jagged-1. Treating the parental cells with DAPT decreased the proteins, such as Jagged-1, Smad-3, and CD44, and induced a significant reduction of Slug in the ICN1 cells [99].

The administration of JLK6 and DAPT led to a significant decrease in the number of colonspheres in SW620 cell lines [100]. Moreover, another study showed that GSI-X treatment suppressed endothelial cell conditioned medium—induced Notch signaling activation and CSC enrichment in HCT116 cells [101].

Treating mice bearing CRC cells with PF-03084014 (125 mg/kg), alone or combined with irinotecan, for 28 days resulted in a significant reduction in tumor recurrence and tumor growth and also decreased the ALDH+ population. This combination therapy had a greater antitumor effect when compared to PF-03084014 or irinotecan alone [102].
5.6. Gastric Cancer

Hayakawa et al. [103] presented a study examining the effect of Notch signaling inhibition on gastric CSC elimination. For this purpose, organoids were co-cultured with 25 µM DAPT for 10 days. The addition of a GSI suppressed the growth of the corpus organoid. For in vivo experiments, the Notch inhibitor dibenzazepine was injected intraperitoneally (30 µmol/kg) into mice for 2 weeks. Dibenzazepine treatment decreased the Mist1-lineage tracing expansion and proliferation in the isthmus.

In another study, the CD44+ population of gastric CSCs was targeted by DAPT, both in vitro and in vivo. In gastric CSCs, DAPT (2.5–15 µM) treatment for 24–96 h decreased the size of the CD44+ population in a time- and concentration-dependent way. This study claimed that DAPT treatment led to the inhibition of the invasion, migration, and proliferation of CD44+ CSC [104].

Epithelial–mesenchymal transition (EMT) is a process associated with tumor initiation, invasion, metastasis, and resistance to therapy. The exposure of CD44− and CD44+ cell lines with DAPT (10 µM) for 72 h suppressed the EMT markers and Hes1 expression, inhibited the CSC properties, and blocked the CD44+ cell proliferation and invasion. In addition, in vivo GSI treatment significantly suppressed the growth of CD44+ cell xenograft tumors [105].

The co-culture of CS12 and MKN45-133+ cells with DAPT (5µM) for a day resulted in the suppression of Notch1 activation and enhancement of CD133 and stemness genes. DAPT also inhibited the sphere-forming ability and decreased the size and number of spheres [106].

DAPT (25–50 µM) alone or in combination with cisplatin reduced the gastric cancer cell viability and decreased the number of CD44highLgr-5high cancer cells, representative of CSC properties. Treatment with GSI alone did not affect cell proliferation [107].

5.7. Head and Neck Cancer

In a study by Chen et al. [108], the administration of DAPT (100 µM), alone or in combination with cetuximab and cisplatin, suppressed the viability of OECM1 cells. DAPT treatment or Kruppel-like factor 4 (KLF4) knockdown led to a significant reduction in the number of KLF4+/CD44+ cells in overexpressing Twist1 OECM1 cells. The combination of DAPT and cetuximab exerted an antitumor effect on xenograft models of head and neck cancers.

The addition of DAPT (1–10 µM), alone or in combination with 5-fluorouracil (5-FU), to esophageal adenocarcinoma OE33 cells inhibited their growth. For in vivo studies, animals were treated with 20 mg/kg DAPT for up to 10 weeks. DAPT treatment suppressed tumor growth, decreased HES1 expression and the level of NICD, and also led to the enhancement of apoptosis and reduction in cell proliferation in vivo. Taken together, Notch signaling inhibition sensitized cancer cells to chemotherapeutic agents and eliminated CSCs [109].

In 2011, Mendelson et al. [110] examined the role of Compound E in Barrett’s esophageal adenocarcinoma. For in vitro studies, cell lines were treated with TGF-β and Compound E (500 nM–5 µM) for 72 h. The results showed that the treatment only suppressed cell proliferation in BE3 cell lines with high Notch signaling and TGF-β dysfunction.

Another study demonstrated that the combination of DAPT (5–10 µM and 10–20 mg/kg) with chemotherapeutic agents (docetaxel, cisplatin, and 5-FU) led to a synergistic increase in chemotherapy-enriched head-neck CSCs, both in vitro and in vivo. Taken together, the inhibition of NOTCH1 signaling reduced the tumor self-renewal capacity and number of CSCs and also decreased transcription factors of self-renewal and markers related to CSCs [111].

The results of another study indicated that NOTCH inhibition (GSI XXI, 5–10 µM) resulted in inhibition of the spheroid-forming ability and also inhibited the survival, migration, and transformation of head and neck squamous cell carcinoma cells [112].
5.8. Liver Cancer and Cholangiocarcinoma

It was demonstrated that treatment with 10 µmol/L of different GSIs (L-685,485 and DAPT) inhibited the growth of the epithelial cell adhesion molecule (EpCAM)-positive fraction in hepatocellular carcinoma cells, and in vivo Notch suppression caused significant antitumor effects in hepatomas, showing that Notch inhibition could block the stem cell properties of hepatic cancer cells [113].

In another study, PF-03084014 suppressed the self-renewal ability and proliferation of CSCs. It also decreased the tumor growth in vivo and inhibited the metastasis of hepatocellular carcinoma to the lung [114].

Cao et al. [115] showed that Notch signaling independent of CSL (CBF1, suppressor of hairless and LAG1) might have an important role in hepatic CSCs, and MRK003 treatment significantly suppressed the sphere-forming capacity and reduced the size of the human stem-like hepatocarcinoma cell population. Similarly, sorafenib and PF-03084014 suppressed the self-renewal ability and proliferation of hepatocellular carcinoma spheroids [116].

One study showed that Notch pathway inhibition by either miR-34a overexpression or treatment with DAPT suppressed the growth and colony-forming ability of human cholangiocarcinoma cells. The results also indicated that targeting miR-34a combined with DAPT is an effective treatment for cholangiocarcinoma [117]. Additionally, the proportion of CD24+CD44+ cells, colony-forming capacity, and mice tumorigenicity were suppressed. A combination of GEM and GSI significantly decreased viable TFK-1 and RBE cells compared with GEM alone [118].

5.9. Lung Cancer

Five studies revealed that DAPT, alone or in combination with cisplatin, suppressed the Notch pathway, reduced the number of primary pulmospheres, decreased the expression of the Notch pathway target genes (Hey1 and Hes1), and reduced the self-renewal capacity of primary spheres [119]; decreased the number of CD133+ cells induced by cisplatin and enhanced the sensitivity to doxorubicin and paclitaxel [120]; decreased the number of CD44+/CD24− cells and inhibited the growth capacity of lung CSCs [121]; significantly decreased the ALDH+ lung cancer cells, and led to cell-cycle arrest, depletion in the number of ALDH+ cancer cells in a concentration-dependent manner, and a reduction in tumor cell proliferation and clonogenicity [122]; and suppressed the proliferation of CD133− and CD133+ cells and had a small effect on the cell cycle [123].

It was demonstrated that RO4929097 (1–10 µmol/L) with or without cisplatin modulated the self-renewing activity of LCSCs via p-STAT3 and HES1 in human non-small cell lung cancer (NSCLC) cells, whereas RO4929097 treatment increased their platinum resistance. Moreover, treatment with RO4929097 inhibited the self-renewal of LCSCs and increased the platinum sensitivity, both in vitro and in vivo [124].

In another study, the exposure of MRK-003 (5–20 µM), with or without docetaxel, inhibited the sphere formation and self-renewal ability and decreased the NICD2 expression. In a mouse tumor xenograft model, MRK-003 reduced the expression of downstream effectors of Notch signaling [125].

PF-03084014 (1 µM) treatment of lung cancer cells, either alone or in combination with erlotinib, resulted in the elimination of the erlotinib-induced stem-like cell population by reducing Notch signaling activity. The inhibition of Notch3 and EGFR receptors decreased the stem-like cell population expansion [126].

Ali et al. [127] reported that in vitro and in vivo treatment of lung adenocarcinoma cells with DBZ, with or without auranofin, led to the inhibition of oncosphere growth, cell viability, soft agar growth, and significantly inhibited tumor growth. This combination therapy resulted in a significantly higher level of inhibition compared with either compound alone.

In vitro treatment with DFPAA decreased the differentiation of NG2+ cells (Sca1hi/CD146−/CD45−/CD31−) into pericytes and reduced the number of neoplastic cells [128].
5.10. Melanoma

In 2016, a study by Kumar et al. [129] investigated the effects of targeting Notch1 on CSC-mediated melanoma progression. Treatment with DAPT and L-685,458 suppressed the expression of CD133 in CD133+ cells and enhanced the number of CD133− cells. The results of this study demonstrated that inhibition of the Notch signaling pathway led to CD133-dependent mitogen-activated protein kinase (MAPK) signaling inhibition and eventually increased the interaction of tumor-associated endothelial cells and the migration of CD133+ cells, and blocked metastasis, melanoma growth, and angiogenesis.

It has also been shown that the Notch pathway has an important role in the differentiation of tumor pericyte precursors. DFPAA treatment led to a reduction in the number of NG2+ cells (oligodendrocyte precursor cells or polydendrocytes) [128].

The effect of the combination of GSIs with a Bcl-2 inhibitor on killing melanoma-initiating cells was investigated in a study. For both in vitro and in vivo studies, GSI-I (0.83 µM) was used, either alone or in combination with ABT-737, for 24–21 days. Combination therapy decreased the cell viability and promoted the non-melanoma-initiating cell apoptosis, inhibited primary sphere formation, decreased the number of ALDH+ cells, and suppressed the melanoma-initiating cells’ self-renewability ability in vitro. In a mouse xenograft model, combination therapy caused a significant decline in the tumor-initiating capacity [130].

In melanoma cancer stem-like cells (MCSLCs), DAPT (10 µM) treatment increased the expression of E-cadherin and inhibited the expression of VE-cadherin and Twist1, demonstrating that DAPT plays an important role in inhibiting melanoma metastasis [131].

5.11. Osteosarcoma

Yu et al. [132] investigated the role of Notch inhibition in the elimination of osteosarcoma stem cells (OSCs). OSCs were treated with 20 µM GSI (DAPT and RO4929097) for 24 h. GSI pretreatment suppressed the spheroid-forming ability and blocked the activity of cisplatin-enriched OSCs. The administration of GSI (DAPT, 10 mg/kg/d) for 14 days in mice bearing chemoresistant xenograft tumors reduced the sarcomsphere-forming ability and suppressed the recurrence of the tumor. GSI treatment also downregulated the expression of stem-like cell markers.

In another study, different osteosarcoma cell lines were exposed to GSI (DAPT, 0–50 µM), alone or in combination with cisplatin, for 8–72 h. Moreover, nude mice were treated with 8 and 10 mg/kg DAPT, intraperitoneally (i.p.), alone or combined with cisplatin (CDDP), for 5 weeks. The study suggested that GSI treatment increased the anti-cancer effect of CDDP in resistant OSCs through the inhibition of proliferation, reduction in motility, induction of apoptosis, and cell-cycle arrest. In addition, GSI treatment reduced the number of OSCs and enhanced the platinum sensitivity of the tumor. It was also shown that the cotreatment of GSI and CDDP suppressed phosphorylated extracellular-regulated kinase (ERK) and Akt, and thus enhanced the antitumor effects. In mice, combination therapy exhibited a greater effect on suppressing the CDDP-resistant tumor xenograft metastasis and growth, compared with the compound alone. Taken together, the GSI and CDDP combination sensitized CDDP-resistant human osteosarcoma cell lines to CDDP through Notch signaling downregulation [133].

5.12. Ovarian Cancer

Vathipadiekal et al. [134] investigated the effect of DAPT on the elimination of ovarian cancer side population cells. The SKOV3 SP and MP cells were cultured with 10 and 20 µg DAPT, for 8 days. DAPT treatment repressed the colony-formation and survival of ovarian cancer side population cells. This side population had a concentration-dependent sensitivity to DAPT treatment.

In another study, primary ovarian tumor cells were exposed to GSI-I (1–10 µM), alone or in combination with cisplatin, for 1–2 days. GSI-I decreased the CSC population and enhanced the tumor platinum-sensitivity. The knockdown of Notch3 using small interfering
RNA increased the platinum therapy response, demonstrating that tumor chemo-sensitivity modulation by GSI-I is Notch signaling specific. In addition, the study demonstrated that the combined treatment of DAPT and cisplatin had a synergistic antitumor effect in Notch-dependent cancer cells through increasing the G(2)/M cell cycle arrest, apoptosis, and DNA-damage response [135].

The treatment of ovarian cancer stem-like cells with DAPT (1–20 µM, 1–3 days) showed that the Notch blockade with DAPT significantly hampered ovarian CSC proliferation and the self-renewal ability, reduced the ovarian cancer stem cell (OCSC)-specific surface marker expression, and decreased the mRNA and protein expression of Sox2 and Oct4 in OCSCs [136].

Recently, the effect of Notch3 signaling pathway suppression was investigated in NR2F6-overexpressing epithelial ovarian cancer (EOC) in vitro and in vivo. RO4929097 (10 µM treatment) enhanced the stem cell phenotype and increased the CDDP resistance in EOC cells by inducing Notch3 activation. RO4929097 treatment also inhibited ovarian cancer cell proliferation and increased apoptosis [137].

### 5.13. Pancreatic Carcinoma

In pancreatic cancer cells, DAPT-induced Notch downregulation led to a reduction in the number of CD133⁺, the inhibition of cell proliferation, and abrogation of the DLL4/Notch-induced chemo-resistance [138], and also resulted in apoptosis, the inhibition of EMT, and the suppression of tumorigenesis by eliminating pancreatic cancer-initiating cells (CD44⁺/EpCAM⁺), both in vitro and vivo [139].

In four different studies, the administration of 1–80 µM DAPT, alone or in combination with leptin, gemcitabine (GEM), and 5-FU, inhibited the Notch pathway, reduced the proliferation of MiaPaCa and BxPC-3 cells, decreased the number of leptin-induced CD133⁺ and ALDH⁺ cells, and inhibited tumorsphere formation [140]. In addition, the number of CM and insulinomas (INS) CSC-enriched spheres decreased, whereas the INS CSC-like cells’ sensitivity to 5-FU improved and the clonogenicity and tumorigenicity of INS CSC-like cells were decreased [141]. The proportion of CD24⁺CD44⁺ cells and pAkt, Hes1, and β-catenin expression in cell lines treated with gemcitabine declined, and the invasion and migration abilities were reduced [142].

DAPT (10–100 nM) and MRK-003 (0.72–5 µM) treatment decreased the number of AcTubHI cells, and in vivo, significantly decreased the abundance of mPanIN epithelial cells expressing Dclk1, which was correlated with blockade of PanIN progression [143].

It was reported that the in vitro and in vivo treatment of cells with different GSIs (MK-0752 and RO4929097), with or without gemcitabine, led to a decrease in the number of CSCs and the inhibition of tumorsphere formation and blocked tumor growth in NOD/SCID mice. Treatment with MK-0752 or RO4929097 combined with gemcitabine displayed the highest percentage of apoptosis compared with either compound alone [144].

MRK-003 with or without gemcitabine downregulated the intracellular domain of the Notch protein (NICD), eliminated the CSCs, and inhibited the colony-forming capacity in pancreatic cancer cells. The combination of gemcitabine and MRK-003 enhanced the antitumor effects, reduced tumor cell proliferation, and led to the induction of intratumoral necrosis and apoptosis [145].

Treating mice bearing pancreatic cancer xenografts with PF-03084014 (150 mg/kg), alone or combined with gemcitabine, downregulated NICD Hey-1 and Hes-1, resulted in tumor regression, and reduced cancer stem cells. The results also showed that combination therapy with gemcitabine and PF-03084014 was effective in apoptosis induction, the suppression of angiogenesis, and tumor cell proliferation, leading to a reduction of primary tumor growth, as well as controlling metastatic dissemination, compared to treatment with gemcitabine alone [146].
Table 1. Potential anti-cancer stem cell (CSC) effects and related mechanisms of action of γ-secretase inhibitors (GSIs) based on in vitro studies.

| Cancer Type               | Cell Type                        | Type and Properties of GSIs | Conc.       | Exposure Time | Major Outcome                                                                 | References          |
|---------------------------|----------------------------------|-----------------------------|-------------|---------------|-------------------------------------------------------------------------------|---------------------|
| Adenoid cystic carcinoma  | Accx11 cells                     | DAPT                        | 1–10 µM     | 24–96 h       | ↓SKP2 and N1ICD, ↓growth of ACC, ↓CD133* cells, ↑p27Kip, ↑radio-sensitivity  | Panaccione et al. [33] |
| Blood (Lymphoma)          | Lymphoma cells                   | L-685,458                   | 0.1–100 µM  | 24 h          | ↓CSCs, ↓colony formation                                                      | Wang et al. [34]    |
| Blood (Lymphoma)          | EL4 and A20 cells 3D cell culture| DAPT                        | 5 µM        | 24 h          | ↓CSCs, ↑sensitivity to doxorubicin                                             | Ikram et al. [35]   |
| Blood (Lymphoma)          | Mono-nuclear cells (MNC)         | DAPT                        | 8–16 µM     | 14 days       | ↓CSCs, ↓colony formation ability, ↓proliferation                              | Gal et al. [36]     |
| Blood (leukemia)          | Tal1/Lmo2 leukemic cells          | MRK-003                     |             | 48 h          | ↓leukemia-initiating cells                                                    | Tatarek et al. [37] |
| Blood (leukemia)          | DND-41, KOPT-K1, Jurkat, NB4, HL60, and OCI/AML-3 cells | Compound E Cy + Qu + Compound E | 10 µM       | 1–7 days | ↓growth, ↓clonogenicity, ↓NOTCH1, ↓CSCs                                       | Okuhashi et al. [38] |
| Blood (leukemia)          | AA and HEL cell lines            | DAPT GSI-XII Compound E     | 20 µM (DAPT) 5 µM (GSI-XII) 10 µM (Compound E) | 1–7 days | ↓cell growth, ↓clonogenicity formation ability, ↑differentiation, ↓CSCs, ↑hemoglobin | Okuhashi et al. [39] |
| Blood (Multiple myeloma)  | Human MM-CSCs                    | RO4929097 RO4929097 + Brucantin | 10 µM     | 24 h          | ↓CSCs, ↓viability, ↓migration, ↓proliferation, ↓angiogenesis                 | Issa et al. [40]    |
| Brain (Glioblastoma)      | GSCs                             | DAPT                        | 25 µM       | 7 days        | ↓proliferation, ↓tumor spheres, ↓CD133 and GLAST, ↓tumor propagation         | Hu et al. [41]      |
| Brain (Glioma)            | U87-MG and LN-22 cell lines      | DAPT                        | 1 µM        | 24 h          | ↓sphere-forming capacity, ↓N1ICD and SOX2 expression                         | Li et al. [42]      |
| Brain (Glioma)            | SHG-44 cell line                 | DAPT                        | 0.5–10 µmol/L | 1–5 days     | ↓proliferation, ↓CSCs, ↓CSC of CD133*                                       | Liu et al. [43]     |
| Cancer Type          | Cell Type                | Type and Properties of GSIs | Conc.   | Exposure Time | Major Outcome                                                                 | References            |
|---------------------|--------------------------|-----------------------------|---------|---------------|-------------------------------------------------------------------------------|----------------------|
| Brain (Glioblastoma) | GBM-derived CD105+ cells | DAPT                        | 5 µM    | 48 h          | ↓transition between CD133+/CD144− and double-positive, ↓CSCs                  | Wang et al. [44]     |
| Brain (Glioblastoma) | Human-derived GBM xenograft cells | DAPT                        | 1–10 µM | 3–14 days     | ↓cell growth, ↓stem cell-like features, ↓CSCs                                | Kristoffersen et al. [45] |
| Brain (medulloblastoma) | Medulloblastoma-derived cells | DAPT                        | 10 µM   | 8–72 h        | ↓HIF-1α and hes1, ↓nestin+ cells, ↓CSCs, ↑β-III-tubulin+ cells, ↑neuronal differentiation | Pistollato et al. [46] |
| Brain (Glioma)       | 029 and 036 neurosphere cultures Human-derived GBM xenograft cells | DAPT                        | 10 µM   | 24 h          | ↓brain CSCs                                                                  | Kristoffersen et al. [47] |
| Brain (Glioma)       | ihBTC2, SU3, SU3-5R, and C6 cells | DAPT + radiation            | 2 µM    | 24 h–8 days   | ↑radio-sensitivity, ↑apoptosis, ↓CSCs                                        | Yuntian et al. [48]  |
| Brain (Glioma)       | A172 cell line           | DAPT + Gleevec + amph1D peptide | 2/5–25 µM | 24–48 h      | ↓CSCs, ↑cell death                                                           | Gal et al. [49]      |
| Brain (medulloblastoma) | D341 cells               | DAPT                        | 2 µM    | 48 h          | ↓Bmi-1, CDK6, c-MYC, and CCND1 expression, ↓CD133+ cells, ↓CSCs                | Wang et al. [50]     |
| Brain (Glioma)       | LN229 and U251 cell lines and primary cells isolated from GBM10 xenograft PDX models | DAPT + imatinib | 20 µM | 1–2 weeks  | ↓growth inhibition, ↓GSCs                                                     | Kanabur et al. [51]  |
| Brain (Glioma)       | U251MG, U87MG, T98G, A172, and U373MG Adherent GBM cell lines 0308 and 0822 GBM stem cell lines | DAPT loaded MLs DAPT + INCB3619 | 12/5–100 µM | 1–6 days | ↓HES1 and HEY1, ↓YKL-40/CHI3L1, ↓CSCs                                        | Floyd et al. [52]    |
| Cancer Type                  | Cell Type                  | Type and Properties of GSIs                                                                 | Conc.                  | Exposure Time | Major Outcome                                                                 | References         |
|-----------------------------|----------------------------|---------------------------------------------------------------------------------------------|------------------------|---------------|-------------------------------------------------------------------------------|--------------------|
| Brain (Glioblastoma)        | GSCs                       | L-685,458 or DAPT                                                                           | 5 µM (L-685,458)      | 3, 7, 14 days | ↓GSCs, ↓sphere-forming cells                                                  | Park et al. [53]   |
| Brain (Glioma)              | U251, U87, A172, and LN18 cells | DAPT BMS-708163 RO4929097 RO4929097 + BMS-708163                                             | 0.5–18 µM             | 72 h          | ↓CSCs                                                                        | Saito et al. [54]  |
| Brain (Glioma)              | T3359, T3691, T4105, T4302, and T4597 cells | DAPT L685,458                                                                             | 2 µM (DAPT) 0.5 µM (L685,458) | 4 h–3 weeks | ↑apoptosis, ↓growth, ↓clonogenic survival of GSCs                               | Wang et al. [55]   |
| Brain (Glioblastoma)        | GBM neurospheres           | GSI-18 MRK-003                                                                             | 2 µM (GSI-18) 2–10 µM (MRK-003) | 2–5 days | ↓CSCs, ↓proliferation, ↑cell death, ↓STAT3 and AKT phosphorylation           | Fan et al. [56]    |
| Brain (Medulloblastoma)     | DAOY, PFSK, D283Med, and D425Med cell lines | GSI-18                                                                                     | 2 µmol/L              | 48 h          | ↓Hes1, ↓mRNA levels, ↓clonogenicity, ↓CSCs                                      | Fan et al. [57]    |
| Brain (Glioblastoma)        | GBM neurosphere cultures   | GSI-18                                                                                     | 2–50 µM              | 48 h          | ↑proliferation, ↑apoptosis, ↑differentiation, ↓CSCs                           | Dai et al. [58]    |
| Brain (Glioma)              | T98G cell lines, human tumor neurospheres, and PDGF-induced glioma primary cells | MRK-003 MRK-003 + GSNO                                                                     | 3 µM                  | 2, 6 h        | ↓side population cells                                                        | Charles et al. [59]|
| Brain (Glioblastoma)        | Primary GBM cell lines     | MRK003                                                                                     | 2 µM                  | 7 days        | ↓neurosphere formation, ↓CSCs                                                 | Fornara et al. [60]|
| Brain (Glioblastoma)        | MD13, 30R, Me83, 1123M, 528P, 157NS, and 146NS cells | MRK003                                                                                     | 1–10 µM              | 2–7 days      | ↓viability, ↓sphere-formation capacity, ↑apoptosis, ↓Akt pathway, ↓CSCs      | Tanaka et al. [61] |
| Brain (Glioma)              | HSR-GBM1 and JHH520 neurosphere lines | MRK003 MRK003 + Chloroquine                                                                | 0.5–5 µM             | 48–72 h       | ↑proliferation, ↓CSCs ↑autophagy, ↓cell growth, ↓colony formation ability    | Natsumeda et al. [62]|
| Brain (Glioma)              | U87 and U251 cell lines    | GSI-I with radiation                                                                       | 1–5 µmol/L           | 4–72 h        | ↓CSCs, ↓CD133+ cells                                                         | Lin et al. [63]    |
Table 1. Cont.

| Cancer Type     | Cell Type                        | Type and Properties of GSIs | Conc.       | Exposure Time | Major Outcome                                                                 | References       |
|-----------------|----------------------------------|-----------------------------|-------------|---------------|-------------------------------------------------------------------------------|------------------|
| Brain (Glioma)  | U87MG cell line                  | GSI-I                       | 5 µmol/L    | 5 days        | ↓CD133⁺ cells, ↓CSCs, ↑TMZ therapeutic effect                                | Ulasov et al. [64]|
| Brain (Glioma)  | PIGPCs                           | MK-003                      | 10 µM       | 24 h          | ↓stem cell markers, ↓glioma primary cultures, ↓CSCs                           | Pietras et al. [65]|
| Brain (Glioma)  | UAB-1005, 1051, 1027A, and 1079 cell lines | RO4929097 + Farnesyltransferase | 20–500 nM | 24–72 h       | ↓AKT, ↓cell-cycle progression, ↑radio-sensitizing, ↓CSCs                     | Ma et al. [66]    |
| Brain (Glioblastoma) | GSCs                            | MK0752                      | 25 µM       | 1–7 days      | ↓self-renewal ability, ↓proliferation, ↓GSCs, ↓secondary neurosphere          | Hu et al. [67]   |
| Brain (Glioblastoma) | GBM neurosphere cultures        | Compound E                  | -           | -             | ↓CSCs                                                                        | Dai et al. [68]  |
| Brain (Glioma)  | U87 cells                        | GSI-II                      | 0.2 µg      | 20 days       | ↓CD133, ↓proliferation, ↓CSCs                                                | Ding et al. [69] |
| Breast          | MCF-7, MDA-MB-468, and MDA-MB-231 cells | DAPT                        | 10 µM       | 12-and/or 24-h | ↓CSCs, ↓ILK-induced Notch activation                                          | Hsu et al. [70]  |
| Breast          | Human TNBC, Hs578T, and MDA-MB-231 cell lines | DAPT                        | 1–5 µm      | 5–12 days     | ↓BCSCs, ↓sphere formation capacity, ↓self-renewal ability, ↓NICD, SCUBE2, HES1 and jagged 1 | Chen et al. [71] |
| Breast          | ZR-75-1, MCF-7, T-47D, JIMT, SK-BR-3, and MDA-MB-231 cell lines | DAPT                        | 2 and 5 µM | 12–24 h       | ↓mammosphere formation, ↓CD44ICD cleavage, ↓CSCs                             | Cho et al. [72]  |
| Breast          | HCC38 and HCC1806 stem cell lines | DAPT                        | 10–40 µM    | 1–14 days     | ↓BCSCs, ↓mammosphere-forming ability, ↓cell invasion, ↓cell proliferation, ↑cell death | Li et al. [73]   |
| Breast          | Trp53−/− mammospheres and TM40A-let7p53KD mammospheres | DAPT                        | 5 µM        | 7 days        | ↓mammary stem/progenitor cells                                               | Tao et al. [74]  |
| Cancer Type | Cell Type | Type and Properties of GSIs | Conc. | Exposure Time | Major Outcome | References |
|------------|-----------|-----------------------------|-------|---------------|---------------|------------|
| Breast     | Athymic nude nu/nu nude mice bearing HCC1806 cells | DAPT | 5 µmol/L | 24–48 h | ↓CSCs, ↓percentage of CD44<sup>hi</sup>/CD24<sup>lo</sup> cells, ↓colony formation ability | McGowan et al. [75] |
| Breast     | MCF7 and MDA231, MDA231LM, and MDA231BoM cell lines | DAPT | 10–20 µM | 24–72 h | ↓Akt, ↓CSCs | Xing et al. [76] |
| Breast     | CAF61a, HCC1937, THP-1, MDA-MB-231 (1833), MDA-MB-436, MDA-MB-231, Hs578T, MDA-MB-157, SKBR3, T47D, MCF7, HCC70, MDA-MB-468 cells | DAPT RT + DAPT | 10 µM | 48 h | ↓mammosphere-forming ability, ↓CD44<sup>+</sup>CD24<sup>low</sup> TRCs, ↑TIC gene expression signature, ↑CSCs | Boelens et al. [77] |
| Breast     | SUM225 and MCF10DCIS cell lines | DAPT DAPT + lapatinib/gefitinib | 0.1, 5, 10, 20 µM | 5, 7, 21 days | ↓acin size, ↓mammosphere formation, ↓ErbB1/2 | Farnie et al. [78] |
| Breast     | T47D, MDA-MB-231, MCF7, BT474 cells | DAPT DAPT + Gefitinib | 10 µM | 24–48 h | ↓CSCs, ↓oestrogen effect | Harrison et al. [79] |
| Breast     | MCF-7 and T47D cell lines | DAPT DAPT + DSL/Tamoxifen | 0/5–1 µM | 24 h | ↓tumoursphere growth, ↓ER-α promoter activity, ↓CSCs, ↓tamoxifen sensitivity | Buckley et al. [80] |
| Breast     | MCF-7 and MDA-MB-231 cells | DAPT DAPT + 6-shogaol | 25–50 µM | 1–7 days | ↓CSCs, ↓proliferation, ↓colony formation capacity, ↓number of spheroids | Ray et al. [81] |
| Breast     | MDA-MB-231 and MCF7 cells | DAPT DAPT loaded glucose-functionalized MSNs | 1 µg | 24 h | ↓CSCs, ↓ALDH activity | Mamaeva et al. [82] |
| Breast     | MCF-7, T47D, and MDA-MB-231 cell lines | GSI-XVII | 5 µM | 30 min | ↓self-renewal, ↓CSCs, ↓primary sphere formation | Phillips et al. [83] |
| Cancer Type | Cell Type | Type and Properties of GSIs | Conc. | Exposure Time | Major Outcome | References |
|-------------|-----------|-----------------------------|-------|---------------|---------------|------------|
| Breast      | SUM159, MCF-7, and T47D cells | GSI-XVII GSI-XVII + radiation | 5 µM  | 1–4 days      | ↓CSCs, ↓DLL3, Notch2, Jagged1, and DLL1 gene expression | Lagadec et al. [84] |
| Breast      | HCC1937, HCC1806, MCF7, T47D, SUM149, and SUM159 cells | GSI-I | 1–10 µM | 24 h | ↓BCSCs | Luo et al. [85] |
| Breast      | MDA-MB-453, HCC1954 and MCF-7 cells | MRK-003 MRK-003 + lapatinib/trastuzumab | 5 µM  | 7 days | ↓CSCs, ↓mammosphere formation, ↓proliferation of bulk HER2+ HCC1954 cells | Shah et al. [86] |
| Breast      | MCF7, MDA-MB 436, MDA-MB 231, ZR-75-1, ZR-75-30, and T47D cell lines | MRK-003 MRK-003 + docetaxel | 10 mmol/L | 1–3 weeks | ↓breast CSCs, ↓self-renewal | D’Angelo et al. [87] |
| Breast      | Primary tumor cells Mammospheres | MRK-003 | 0.01–10 µM | 2–4 days | ↓proliferation, ↓self-renewal ability, ↑apoptosis, ↑differentiation, ↓CSCs | Kondratyev et al. [88] |
| Breast      | MDA-MB231, MDA-MB231BrM, CN34, and CN34BrM cells | DAPT | 5–10 µM | 48–72 h | ↓CSCs, ↓HES5 | Xing et al. [89] |
| Breast      | ZR-75, MCF-7, and MDA-231 cell lines | compound E DAPT DAPT +AD-01 | 0.025–1.25 µmol/L (compound E) 10 µmol/L (DAPT) | 72 h | ↓BCSCs, ↓MSFE | McClements et al. [90] |
| Breast      | MCF7, MDA-MB-231, and BT474 cells | DAPT DBZ | 10 µmol/L | 3–7 days | ↓ESA+/CD44+/CD24low cells, N1-ICD, ↓HEY2 and HES1, ↓CSCs | Harrison et al. [91] |
| Breast      | MCF7, T47D-A18, T47D-C42, BT474, and SKBR3 cells | MRK003 GSI-I LY-411,575 | GSI-I (0.5 µM), MRK003 (10–20 µM), LY-411, 575 (25–50 µM) | 24–48 h 12–28 days | ↓CSCs, ↓mammosphere formation | Grudzien et al. [92] |
| Cancer Type   | Cell Type                          | Type and Properties of GSIs       | Conc.   | Exposure Time | Major Outcome                                                                                   | References        |
|--------------|------------------------------------|-----------------------------------|---------|--------------|-----------------------------------------------------------------------------------------------|-------------------|
| Breast       | SUM149 and SUM159, MCF-7, MDA-MB-231, and HCC1954 cell lines | RO4929097                         | 10 µM   | 7 days       | ↓BCSCs                                                                                         | Wang et al. [93]  |
| Breast       | MDA-MB-231-luc and MCF-10A cells   | DAPT                              | 5–10 µM | 1–12 days    | ↓CSCs, ↓N1-ICD, ↓Sox2, ↓sphere formation ability                                             | Azzam et al. [94] |
| Breast       | SUM149 and SUM190 cells            | RO4929097                         | 0.1 nM–10 µM | 24–14 days | ↓Hey1, HeyL, and Hes1, ↓colony-forming capacity, ↓CSCs, ↓TNF-α, IL-8, and IL-6, ↑sensitivity to ionizing radiation | G. Debeb et al. [87] |
| Cholangiocarcinoma | CCLP1, SG231, HUCCT1, and TFK1 cells | DAPT                              | 10–40 µM | 24–72 h, 10–14 days | ↓growth, ↓colony formation, ↓CSCs                                                               | Kwon et al. [117] |
| Cholangiocarcinoma | HuCCT1, TFK-1, and RBE cell lines | DAPT                              | 20–40 µM | 1–4 days    | ↓CD24⁺CD44⁺ cells, ↓colony-forming capacity, ↓CSCs                                             | Aoki et al. [118] |
| Colorectal   | IEC-6/KRAS G12V cells              | DAPT                              | 10–20 µmol/L | 24 h      | ↓CSCs, ↓Hes1                                                                                   | Feng et al. [96]  |
| Colorectal   | CCSC cells                         | DAPT                              |         |             | ↓CCSCs, ↓symmetric CCSC-CCSC division, ↓asymmetric division, ↑non-CCSCs                          | Bu et al. [98]    |
| Colorectal   | HCT-116 cell line                  | DAPT                              | 10 µM   | 1–10 days   | ↓CSCs, ↓Smad-3, Jagged-1, and CD44, ↓Slug                                                        | Fender et al. [99]|
| Colorectal   | Caco-2 and SW620 cell lines        | DAPT                              | 2.5–10 µM (JLK6) | 1 h–14 days | ↓colosphere formation, ↓CSCs                                                                    | Moon et al. [100] |
| Colorectal   | HCT116 cells                       | L-685,458                         |         |             | ↓CSCs, ↓NICD upregulation, ↓Aldefluor-positive cell population                                 | Lu et al. [101]   |
| Cancer Type | Cell Type | Type and Properties of GSIs | Conc. | Exposure Time | Major Outcome | References |
|-------------|-----------|-----------------------------|-------|---------------|---------------|------------|
| Gastric     | Human gastric cancer cell lines, corpus gland cultures, and Mist1+ stem cells | DAPT | 25 µM | 10 days | ↓Mist1+ stem cell proliferation | Hayakawa et al. [103] |
| Gastric     | MKN45 cell line | DAPT | 2.5–15 µM | 24–96 h | ↓CSCs, ↓proliferation, ↓CD44+ cells | Barat et al. [104] |
| Gastric     | MKN-45 cells | DAPT | 10 µM | 72 h | ↓CSCs, ↓EMT markers, ↓Hes1, ↓proliferation | Li et al. [105] |
| Gastric     | GI2, CS12, MKN45 cells | DAPT | 5 µM | 24 h | ↓sphere-forming ability, ↓sphere size and number, ↓stemness genes and CD133 | Hong et al. [106] |
| Gastric     | SC-6-JCK, SH-10-TC, MKN74, and MKN45 cells | DAPT + Cisplatin | 25–50 µM | 24–72 h | ↓CSCs, ↓cell viability, ↓CD44highLgr-5high population | Kato et al. [107] |
| Head and neck | SAS, OECM1, and FADU cells | DAPT + Cetuximab | 100 µM | 1–14 days | ↓KLF4+/CD44+ cells | Chen et al. [108] |
| Head and neck | OE33, OE19, FLO1, JH-EsoAd1 cells | DAPT + 5-FU | 1–10 µM | 1–7 days | ↓CSCs, ↓HES1 expression, ↑NICD, ↑apoptosis, ↑proliferation, ↑sensitivity to chemotherapeutic agents | Wang et al. [109] |
| Head and neck | FLO-1, SKGT-4, BE3, and OE33 cells | Compound E | 500 nM–5 µM | 72 h | ↓CSCs, ↓proliferation | Mendelson et al. [110] |
| Head and neck | CAL27 and FaDu cell lines | DAPT + chemotherapeutic agents | 5–10 µM | 1–14 days | ↓CSCs, ↓CSCs markers | Zhao et al. [111] |
| Head and neck | AW13516, NT8e, CAL27, DOK cells | Compound E | 5–10 µM | 20 h–21 days | ↓CSCs, ↓spheroid-forming ability, ↓survival, migration, and transformation of the HNSCC cells | Upadhyay et al. [112] |
| Cancer Type | Cell Type | Type and Properties of GSIs | Conc. | Exposure Time | Major Outcome | References |
|-------------|-----------|------------------------------|-------|---------------|---------------|------------|
| Liver       | Huh7, Huh6, HepG2, Hep3B, PLC/PRF/5, SKHep1, HLE, and THLE-5b cells | L-685,485 DAPT | 10 µmol/L | 24–168 h | ↓cell growth EpCAM⁺ cells, ↓CSCs, ↓HES1 | Kawaguchi et al. [113] |
| Liver       | Hep3B, Huh7, PLC, MHCC97L, and MHCC97H cells Liver cancer spheres | PF-03084014 | 0.25–2 µM | 1–14 days | ↓CSCs, ↓proliferation, ↓self-renewal ability | Wu et al. [114] |
| Liver       | MHCC97H, PLC/PRF/5, and HepG2 cells Liver cancer spheres | MRK003 | 10 µM | 1–7 days | ↓CSCs, ↓sphere formation ability | Cao et al. [115] |
| Liver       | MHCC97H and MHCC97L cells | PF-03084014 PF-03084014 + sorafenib | 0.1–0.25 µM | 24 h | ↓CSCs, ↓self-renewal ability, ↓proliferation, ↓spheroid formation | Yang et al. [116] |
| Lung        | NSCLC tumor-propagating Cells | DAPT | 100 µM | 1–2 weeks | ↓self-renewal, ↓tumor propagation, ↓Hes1 and Hey1, ↓CSCs | Zheng et al. [119] |
| Lung        | A549, H460, PC9, H1299, and H661 cells | DAPT DAPT + Cisplatin | 10 µmol/L | 30 min–48 h | ↓CD133⁺ cells, ↑sensitivity to doxorubicin and paclitaxel, ↓Hes-1 | Liu et al. [120] |
| Lung        | A549 human lung adenocarcinoma cell line | DAPT | 25–75 µM | 48 h | ↓LCSCs, ↓CD44⁺/CD24⁻ cells | Cai et al. [121] |
| Lung        | NSCLC and SCLC cells | DAPT | 25 µmol/L | 3–14 days | ↓ALDH⁺ cancer cells, ↓proliferation, ↓clonogenicity, ↓cell-cycle arrest, ↓CSCs | Sullivan et al. [122] |
| Lung        | A549 cell line | DAPT CDDP + DAPT | 2 µM | 48 h | ↑cell-cycle arrest, ↓CSCs, ↓proliferation of CD133⁺ and CD133⁻ cells | Liu et al. [123] |
| Lung        | LCSCs and NSCLC cells | RO4929097 | 1–10 µM | 24–48 h | ↓p-STAT3, ↓self-renewal, ↓LCSCs, ↓HES1 | Zhang et al. [124] |
| Cancer Type | Cell Type | Type and Properties of GSiS | Conc. | Exposure Time | Major Outcome | References |
|-------------|-----------|-----------------------------|-------|---------------|---------------|------------|
| Lung        | H1299, H441, H460, H358, and A549 cells | MRK-003 and MRK-003 + Docetaxel | 5–20 µM | 24–48 h | ↓CSCs, ↓sphere formation ability, ↓self-renewal, ↓NICD2 | Hassan et al. [125] |
| Lung        | HCC2429, HCC827, H358, and HCC4006 cells | PF-03084014 + erlotinib | 1 µM | 7 days | ↓CSCs, ↓ALDH+ cells, ↓EGFR | Arasada et al. [126] |
| Lung        | H23, A549, H358, H661, H1437, H1299, H1703, H520, and ChagoK1 cells | DBZ | 5 µM | 3–30 days | ↓onsosphere growth, ↓cell viability, ↓soft agar growth | Ali et al. [127] |
| Lung        | LLC cells | DFPAA | - | 7 days | ↓NG2+ cells, ↓CSCs | Patenaude et al. [128] |
| Melanoma    | B16F10 cells | DFPAA | - | 7 days | ↓NG2+ cells, ↓CSCs | Patenaude et al. [128] |
| Melanoma    | B16F10 and B16F1, SK-MEL-28, A375, and SK-MEL-2 cell lines | DAPT and L-685,458 | 5–15 µM | 12 h–4 weeks | ↓CSCs, ↓CD133, ↓metastasis, ↓melanoma growth, ↓angiogenesis, ↓CD133-dependent MAPK signaling | Kumar et al. [129] |
| Melanoma    | WM852c, SK-MEL 28, 1205Lu, HT144, A375, and 451Lu cells | GSI-I | 0.83 µM | 24–48 h | ↓primary sphere formation, ↓ALDH+ cells, ↓cell viability, ↑apoptosis of the non-MICs, ↓self-renewability | Mukherjee et al. [130] |
| Melanoma    | B16F10, A375, A875, MUM-2C, and MUM-2B cell lines Tumorospheres and the multicellular tumor spheroid (MTS) model | DAPT | 10 µM | 24–72 h | ↓CSCs, ↑E-cadherin, ↓VE-cadherin and Twist1, ↓metastasis | Lin et al. [131] |
| Osteosarcoma | U2OS, 143B, and MG63 cell lines | DAPT RO4929097 | 20 µM | 24 h | ↓spheroid-forming ability, ↓CSCs | Yu et al. [132] |
| Cancer Type | Cell Type | Type and Properties of GSIs | Conc. | Exposure Time | Major Outcome | References |
|-------------|-----------|-----------------------------|-------|--------------|---------------|------------|
| Osteosarcoma | 143B, U2OS, and MG-63 cell lines | DAPT DAPT + Cisplatin | 5–50 µM | 24–72 h | ↓OSCs, ↓proliferation, ↓motility, ↑apoptosis, ↑cell-cycle arrest, ↑platinum-sensitivity, ↓ERK and AKT | Dai et al. [133] |
| Ovarian | SKOV3, A224, OVCAR-3, and UCI-107 cell lines | DAPT | 10–20 µg | 8 days | ↓Colony-formation, ↓SP cells | Vathipadiekal et al. [134] |
| Ovarian | 4412, 4306, OVCAR5, PA-1, OVCAR3, IGROV1, A2780, SKOV3, and OV2008 cells | GSI-I GSI-I + platinum | 1–10 µM | 1–3 days | ↑tumor platinum-sensitivity, ↓CSCs, ↑cell-cycle arrest, apoptosis, and DNA-damage | McAuliffe et al. [135] |
| Ovarian | SKOV3 and HO8910 cell lines | DAPT | 1–20 µg/mL | 1–3 days | ↓self-renewal ability, ↓proliferation, ↓CSCs, ↓OCSCs-specific surface markers expression, ↓Sox2 and Oct4 | Jiang et al. [136] |
| Ovarian | OVCAR3 and A2780 cells | RO4929097 RO4929097 + CDDP | 10 µM 10 mg/kg | 24 h | ↓proliferation, ↑apoptosis, ↓CSCs | Li et al. [137] |
| Pancreatic | Bxpc-3 and Panc-1 cell lines | DAPT | 1 and 10 µM | 48 h | ↓CD133+, ↓proliferation, ↓CSCs, ↓chemo-resistance | Kang et al. [138] |
| Pancreatic | BxPC3, KP3 cells | DAPT | 2.5–10 µM | 48–96 h | ↑apoptosis, ↓CSCs, ↓EMT | Palagani et al. [139] |
| Pancreatic | Panc-1, BxPC-3, MiaPaCa-2, AsPC-1 cell lines | DAPT DAPT + leptin | 20 µM | 1–10 days | ↓PCSCs, ↓proliferation, ↓leptin-induced CD133+ and ALDH1+ cells, ↓tumorsphere formation | Harbuzariu et al. [140] |
| Pancreatic | CM cell line | DAPT DAPT + 5-FU | 2–80 µg/mL | 24–48 h | ↓clonogenicity, ↑sensitivity to 5-FU, ↓CSC-enriched spheres | Capodanno et al. [141] |
Table 1. Cont.

| Cancer Type | Cell Type | Type and Properties of GSIs | Conc. | Exposure Time | Major Outcome | References |
|-------------|-----------|-----------------------------|-------|---------------|---------------|------------|
| Pancreatic  | BxPC3 and HPAC cells | DAPT Gem + DAPT | 20 µM | 72 h | ↓CSCs, ↓CD24+CD44+ cells, ↓pAKT, Hes1, and β-catenin expression, ↓invasion, ↓migration | Lee et al. [142] |
| Pancreatic  | DCLKHI/AcTubHI cells | DAPTMRK-300 | DAPT (10–100 nM) MRK-300 (0.72–5 µM) | 3–4 days | ↓CSCs, ↓AcTubHI cells, ↓PanIN progression, ↓mPanIN epithelial cells expressing Dclk1 | Bailey et al. [143] |
| Pancreatic  | Pancreatic cancer cells | MK-0752 GSI + gemcitabine | 8 µM | 24–72 h | ↓CSCs, ↓tumorsphere formation, ↑apoptosis | Abel et al. [144] |
| Pancreatic  | Pa03C, Pa14C, Pa16C, and Pa29C cells | MRK-003 MRK-003 + GEM | 2–5 µM | 48 h | ↓CSCs, ↓NICD, ↓colony-forming capacity, ↑apoptosis | Mizuma et al. [145] |
| Prostate    | DU145 and TRAMP-C2 cell lines and PCSCs | PF-03084014 | 0/01–100 µM | 6 days | ↓PCSCs | Wang et al. [147] |
| Prostate    | VCaP and LnCaP96 cell lines | DAPT | 1 nM–400 µM | 48–96 h | ↓CSCs, ↓NICD1 | Carvalho et al. [148] |
| Prostate    | Du145, PC3, Du145R, and PC3R cells | PF-03084014 PF-03084014 + docetaxel | 0.1–10 µM | 48 h | ↓CSCs, ↑apoptosis, ↑epithelial to mesenchymal transition, ↓(cyclin E; EGFR, PI3K/AKT, NF-κB, and NF-xB pathway; BCL-XL, BCL-2) | Cui et al. [149] |

Abbreviations: 5-FU, fluorouracil; ACC, adenoid cystic carcinoma; ALDH, aldehyde dehydrogenases; Bcl-2, B-cell lymphoma 2; Bcl-XL, B-cell lymphoma-extra-large; BCSCs, breast cancer stem cells; CCSC, colorectal cancer stem cell; CD44, cluster of differentiation-44; CD44ICD, CD44 intracytoplasmic domain; CDDP, cisplatin; CHI3L1, chitinase-3-like protein 1; CSCs, cancer stem cells; Cy, cycloamine; DLL1, Delta-like ligand 1; DLL3, Delta-like ligand 3; Delk1, Doublecortin-like kinase 1; DBZ, dibenzazepine; E-cadherin, epithelial cadherin; EGFR, epidermal growth factor receptor; EMT, epithelial–mesenchymal transition; EpCAM, epithelial cell adhesion molecule; ER-α, estrogen receptor α; ErbB, epidermal growth factor receptors; ERK, extracellular-regulated kinase; GEM, gemcitabine; GLAST, glutamate aspartate transporter; GSCs, glioma stem cells; GSNO, S-nitrosoglutathione; HIF1α, hypoxia-inducible factor 1α; HNSCC, head and neck squamous cell carcinoma; IL-6, interleukin 6; IL-8, interleukin-8; ILK, integrin-linked kinase; KLF4, Kruppel-like factor 4; LCSCs, lung cancer stem cells; Lgr-5, leucine-rich repeat-containing G-protein coupled receptor 5; MAPK, mitogen-activated protein kinase; Mist1, Muscle, intestine, and stomach expression 1; mPanIN, murine pancreatic intraepithelial neoplasia; MSFE, mammosphere-forming efficiency; NF-κB, nuclear factor-κB; NICD, Notch intracellular domain; N1-ICD, Notch1 intracellular domain; Oct4, octamer-binding transcription factor 4; OScs, osteosarcoma stem cells; PanIN, pancreatic intraepithelial neoplasia; PCSCs, prostate cancer stem cells; PI3K, phosphatidylinositol-3-kinase; p-STAT3, phosphorylated-signal transducer and activator of transcription 3; Qu, quercetin; RT, radiation; SCUBE2, signal peptide CUB EGF-like domain-containing protein 2; SKP2, S-phase kinase-associated protein 2; SOX2, SRY-box transcription factor 2; SP cells, side population cells; STAT3, signal transducer and activator of transcription 3; TIC, tumor initiating cell; TMZ, temozolomide; TNF-α, tumor necrosis factor-α; TPA, tetradecanoyl phorbol acetate; Twist1, Twist family BHLH transcription factor 1; VE-cadherin, vascular endothelial-cadherin.
Table 2. Potential anti-CSC effects and related mechanisms of action of GSIs based on in vivo studies.

| Cancer Type                        | Animal Model                                      | Type and Properties of GSIs | Dose    | Exposure time | Major Outcome                                      | References                  |
|-----------------------------------|---------------------------------------------------|-----------------------------|---------|---------------|----------------------------------------------------|-----------------------------|
| Adenoid cystic carcinoma          | Athymic NCr-nu/nu mice bearing Acssx11 cells       | DAPT DAPT + radiation       | 50 mg/kg| 35 days       | ↓SKP2 and N1ICD, ↓growth of ACC, ↓CD133+ cells, ↑p27Kip, ↑radio-sensitivity | Panaccione et al. [33]      |
| Blood (leukemia)                  | Tal1/Lmo2 transgenic mice bearing Tal1/Lmo2 leukemic cells | MRK-003                     | 150 mg/kg| 1–3 weeks     | ↓leukemia-initiating cells                          | Tatarek et al. [37]         |
| Brain (Glioma)                    | Immune-compromised mice bearing GBM neurosphere cells | DAPT                        | 10 µM   | 7 days        | ↓brain CSCs                                        | Kristoffersen et al. [47]   |
| Brain (medulloblastoma)           | BALB/c nude mice xenograft models                 | DAPT DAPT + HBMED/D341Med    |         | 40 days       | ↓tumor size and volume                             | Wang et al. [50]            |
| Brain (Glioma)                    | Balb/c mice bearing GBM stem cells                | DAPT GSI-loaded MLs DAPT + INCB3619 | 0.5 mg/mL| 3 weeks       | ↑survival rate, ↓CSCs                              | Floyd et al. [52]           |
| Brain (Glioma)                    | Nude (nu/nu) mice bearing GICT25 cells            | DAPT BMS-708163 RO4929097    | 10 mg/kg (RO4929097) 20 mg/kg (BKM120) | 5 weeks | ↓tumor growth, ↑survival rate                       | Saito et al. [54]           |
| Brain (Glioma)                    | Flank and Intracranial Xenograft tumors nude mice bearing GBM neurosphere cells | GSI-18 MRK-003              | 2 µM (GSI-18) 2–10 µM (MRK-003) | 6 weeks | ↓tumor growth, ↑survival rate                       | Fan et al. [56]             |
| Brain (Medulloblastoma)           | Athymic (nude) mice tumor xenografts              | GSI-18                       | 0/5 mg  | 5 days        | ↓clonogenicity, ↓tumor growth                      | Fan et al. [57]             |
| Brain (Glioma)                    | Subcutaneous Xenografts Athymic Nude Mice bearing U251 cells | GSI-I with radiaton          | 2.5 mmol/L | 2–4 weeks     | ↓tumor growth                                      | Lin et al. [63]             |
Table 2. Cont.

| Cancer Type              | Animal Model                                                                 | Type and Properties of GSIs                        | Dose     | Exposure time | Major Outcome                                                                                     | References          |
|--------------------------|------------------------------------------------------------------------------|---------------------------------------------------|----------|---------------|---------------------------------------------------------------------------------------------------|---------------------|
| Brain (Glioma)           | Immunocompromised mice bearing U87-MG cells                                  | GSI-I, GSI-I + TMZ/cyclopamine                                                                 | −        | −             | ↓CD133+ cells, ↓CSCs, ↑TMZ therapeutic effect                                                   | Ulasov et al. [64]  |
| Brain (Glioma)           | T4302, T4105, and T4597 xenograft tumors                                     | RO4929097, RO4929097 + Farnesyltransferase       | 30 mg/kg | 5–20 days     | ↑radio-sensitizing, ↓tumor growth                                                                 | Ma et al. [66]       |
| Breast                   | Athymic nude nu/nu mice bearing HCC1806 cells                               | DAPT                                             | 10–40 µM | 7–21 days     | ↓tumor formation                                                                                  | Li et al. [73]      |
| Breast                   | Athymic nude nu/nu mice bearing 231-BR cells                                | DAPT                                             | 8 mg/kg  | 14 days       | ↓micro- and macro-metastases                                                                      | McGowan et al. [75] |
| Breast                   | Nude mice bearing MDA231BoM cells                                           | DAPT                                             | −        | −             | ↓invasion                                                                                        | Xing et al. [76]    |
| Breast                   | Nude mice bearing MDA-MB-231 1833 cells                                      | DAPT RT + DAPT                                   | 10 mg/kg | 0–20 days     | ↓tumor growth                                                                                    | Boelens et al. [77] |
| Breast                   | NSG mice bearing breast CSCs                                                | DAPT, DAPT + Gefitinib                          |          |               | ↓Oestrogen effect                                                                                 | Harrison et al. [79]|
| Breast                   | Chicken eggs                                                                 | DAPT DAPT loaded glucose-functionalized MSNs     | 5 µg/mL  | 5 days        | ↓number of cancer cells per mg/tissue                                                             | Mamaeva et al. [82] |
| Breast                   | NOD/SCID mice bearing Sum159 and MCF7 cells                                | MRK-003, MRK-003 + docetaxel                     | 75 mg/kg | 3–10 weeks    | ↓breast CSCs, ↓self-renewal, ↓tumor initiation ability                                             | D’Angelo et al. [87]|
| Breast                   | FVB/N mice bearing mammospheres                                             | MRK-003                                          | 150 mg/kg| 2 weeks       | ↓viability, ↓reduced tumor-resident TIC                                                             | Kondratyev et al. [88]|
| Breast                   | NOD/SCID mouse bearing MDA-MB231, MDA-MB231BrM, CN34, and CN34BrM cells     | Compound E                                       | 10 mg/kg | 4 weeks       | ↓growth, ↓metastasis                                                                             | Xing et al. [89]    |
| Cancer Type | Animal Model | Type and Properties of GSIs | Dose | Exposure time | Major Outcome | References |
|-------------|--------------|-----------------------------|------|---------------|---------------|------------|
| Breast      | Athymic nude mice bearing MCF7, MDA-MB-231, and BT474 cells | DBZ | 1 mg/mL | 18–28 days | ↓tumor size and volume, ↑mice latency | Harrison et al. [91] |
| Breast      | Nude mice bearing SUM149 cells | MK-0752 | 25 µM and 25 mg/kg | 10 weeks | ↓primary and secondary MSFE, ↓ALDH+ and CD44+/CD24- subpopulations, ↓NICD, ↓Hes1, Hey1, Hes5, and myc, ↓tumor growth, ↓BCSCs | Wang et al. [93] |
| Breast      | SCID/Beige mice bearing human tumors | MK-0752 MK-0752 + Docetaxel | 100 mg/kg | 3–21 days | ↓tumor growth, ↓NICD, ↓Hes1, Hey1, Hes5, and myc, ↓tumor growth, ↓BCSCs | Schott et al. [31] |
| Breast      | Balb/C nude mice bearing MDA-MB-231-luc cells | RO4920927 | 30 mg/kg/day | 2 weeks | ↓tumor growth | Azzam et al. [94] |
| Cholangiocarcinoma | (NOD/SCID) female mice bearing HuCCT1, TFK-1 and RBE cell lines | DAPT DAPT + GEM | 40 µM | 10 days | ↓mice tumorigenicity, ↓viability | Aoki et al. [118] |
| Colorectal | Lgr5-EGFP-creERT² transgenic mouse bearing colorectal cancer cells | DAPT | – | – | ↓Lgr5-GFP+, ISC, ↓Ascl2 levels, ↓CSCs | Bu et al. [97] |
| Colorectal | athymic (nu+/nu-) mice bearing CRC cells | PF-03084014 PF-03084014 + irinotecan | 125 mg/kg | 28 days | ↓tumor recurrence, ↓tumor growth, ↓ALDH+ population, ↓CSCs | Arcaroli et al. [102] |
| Gastric | Mist1- CreERT2;R26-mTmG mice bearing gastric cancer cells | DBZ | 30 µmol/kg | 14 days | ↓corpus organoid growth | Hayakawa et al. [103] |
| Gastric | Nude mice bearing MKN45 cells | DAPT | 10 mg/kg/body weight | 1 week | ↓migration, ↓invasion | Barat et al. [104] |
| Gastric | Nude mice bearing MKN-45 cells | DAPT | 10 mg/kg/body weight | 5 weeks | ↓tumor growth, ↓invasion | Li et al. [105] |
| Head and neck | Balb/c Nude mice bearing, SAS, OECM1, and FADU cells | DAPT DAPT + Cetuximab | 100 mg/kg | 6 weeks | ↓viability, ↓tumor growth | Chen et al. [108] |
| Cancer Type       | Animal Model                                                                 | Type and Properties of GSIs                  | Dose          | Exposure time | Major Outcome                                                                 | References         |
|------------------|------------------------------------------------------------------------------|---------------------------------------------|---------------|---------------|-------------------------------------------------------------------------------|-------------------|
| Head and neck    | Immunocompromised mice bearing esophageal adenocarcinoma cells               | DAPT DAPT + 5-FU                            | 20 mg/kg      | 2–10 weeks    | ↓ tumor growth, sensitivity to chemotherapeutic agents                        | Wang et al. [109] |
| Head and neck    | BALB/c nude mice bearing CAL27 or SCC9 cells                                 | DAPT DAPT + chemotherapeutic agents         | 10–20 mg/kg   | 2 weeks       | ↓ tumor self-renewal capacity                                                  | Zhao et al. [111]  |
| Liver            | NOD-SCID mouse bearing Huh7 cells                                            | L-685,485 DAPT                              | 5 mg/kg (L-685,458) 20 mg/kg (DAPT) | 2,6 weeks | ↓ tumor growth                                                               | Kawaguchi et al. [113] |
| Liver            | Nude or SCID-beige mice bearing MHCC97H and MHCC97L cells                   | PF-03084014                                 | 100 mg/kg     | 4 weeks       | ↓ tumor metastasis                                                            | Wu et al. [114]    |
| Liver            | SCID mice bearing 97H spheroid-derived cancer cells                         | PF-03084014 + sorafenib                    | 100 mg/kg/day | 2–4 weeks    | ↓ spheroid formation                                                          | Yang et al. [116]  |
| Lung             | Nude mice bearing H460 cells                                                 | DAPT DAPT + Cisplatin                       | 2 mg/kg       | 4 days        | ↑ sensitivity to doxorubicin and paclitaxel                                    | Liu et al. [120]   |
| Lung             | NSG mice bearing LCSCs and NSCLC cells                                       | RO4929097                                   | 5 mg/kg       | 10 days       | ↑ platinum sensitivity                                                        | Zhang et al. [124] |
| Lung             | NOD/SCID mice bearing H1299 cells                                           | MRK-003 and MRK-003 + Docetaxel             | -             | 3 weeks       | ↓ tumorigenicity                                                              | Hassan et al. [125]|
| Lung             | Immunodeficient mice bearing AS49 cells                                      | DBZ DBZ + ANF                               | 200 µg/kg     | 8 weeks       | ↓ tumor growth                                                                | Ali et al. [127]   |
| Melanoma         | NCRNU nude mice bearing HT144 and WM852c cells                              | GSI-I GSI-I + ABT-737                       | 0.83 µM       | 21 days       | ↓ tumor-initiating capacity                                                   | Mukherjee et al. [130] |
| Osteosarcoma     | NOD/SCID mice bearing 143B cells                                            | DAPT                                         | 10 mg/kg/d    | 2 weeks       | ↓ tumor recurrence                                                            | Yu et al. [132]    |
| Osteosarcoma     | BALB/c-nu/nu nude mice bearing 143B cells                                   | DAPT DAPT + Cisplatin                       | 8–10 mg/kg/d  | 5 weeks       | ↑ platinum-sensitivity, metastasis, tumor growth                              | Dai et al. [133]   |
| Ovarian          | Balb/C athymic mice bearing SKOV3-SP and MP cells                           | DAPT                                         | 5 mg/mL       | 8 weeks       | ↓ Colony-formation, SP cells                                                  | Vathipadiekal et al. [134] |
| Cancer Type | Animal Model | Type and Properties of GSIs | Dose | Exposure time | Major Outcome | References |
|-------------|--------------|----------------------------|------|--------------|--------------|------------|
| Ovarian     | SCID mouse bearing PA-1/luc, OVCAR5/luc, and SKOV3/luc cells Tumor xenografts | GSI-I GSI-I + platinum | 5 mg/kg | 18 days | ↑tumor platinum-sensitivity | McAuliffe et al. [135] |
| Ovarian     | BALB/c nude mice bearing OVCAR3 and A2780 cells | RO4929097 RO4929097 + CDDP | 10 mg/kg | 6 weeks | ↓tumor growth, ↓tumor volume | Li et al. [137] |
| Pancreatic  | Nude mice bearing BxPC3, KP3 cells | DAPT | 10 mg/kg/body weight | 5 weeks | ↓tumorigenesis | Palagani et al. [139] |
| Pancreatic  | Chicken eggs | DAPT DAPT + 5-FU | 2–80 µg/mL | 11 days | ↓tumourigenicity, ↑sensitivity to 5-FU | Capodanno et al. [141] |
| Pancreatic  | KC/Pdx1, KPC/Pdx1, and KC/iMist mice bearing pancreatic cancer cells | MRK-300 | 100 mg/kg | 11–13 weeks | ↓tumorigenesis, ↓Dclk1-expressing cells | Bailey et al. [143] |
| Pancreatic  | NOD/SCID mice bearing pancreatic cancer cells | RO4929097 GSI + gemcitabine | 30 mg/kg | 5 days | ↓tumor growth | Abel et al. [144] |
| Pancreatic  | athymic nude mice bearing Pa03C, Pa14C, Pa16C, and Pa29C cells | MRK-003 MRK-003 + GEM | 150 mg/kg | 3 weeks | ↓tumor cell proliferation, ↑intratumoral necrosis | Mizuma et al. [145] |
| Prostate    | nu/nu athymic mice bearing Panc215, Panc266, Panc354, and Panc265 xenografts | PF-03084014 PF-03084014 + GEM | 150 mg/kg | 4 weeks | ↓NICD, ↓Hes-1 and Hey-1, ↓CSCs, ↓angiogenesis, ↓proliferation, ↓tumor growth, ↓metastasis, ↑apoptosis, ↑angiogenesis, ↑tumor regression | Yabuuchi et al. [146] |
| Prostate    | (NOD/SCID) mice bearing Du145, Du145R, PC3, and PC3R cells | PF-03084014 PF-03084014 + docetaxel | 150 mg/kg | 4 weeks | ↓tumor growth | Cui et al. [149] |

Abbreviations: 5-FU, fluorouracil; ACC, adenoid cystic carcinoma; ALDH, aldehyde dehydrogenases; Ascl2 levels, achaetescute-like 2; Dclk1, Doublecortin-like kinase 1; DBZ, dibenzazepine; E-cadherin, epithelial cadherin; GEM, gemcitabine; ISC, intestinal/colon stem cell; KLF4, Kruppel-like factor 4; LCSCs, lung cancer stem cells; Lgr-5, leucine-rich repeat-containing G-protein coupled receptor 5; Mist1, Muscle, intestine and stomach expression 1; NICD, Notch intracellular domain; SKP2, S-phase kinase-associated protein 2; TIC, tumor initiating cell; TMZ, temozolomide.
5.14. Prostate Cancer

In a recently published study, Wang et al. [147] investigated the antitumor effect of PF-03084014 on prostate cancer. Prostatic cancer stem cells were exposed to 1–100 µM PF-03084014 in combination with oncolytic herpes simplex virus for 6 days. The results of this study showed a reduction in the cancer cell population.

It was shown that DAPT (1 nM–400 µM) treatment reduced the protein levels of NICD1 and blocked γ-secretase activity in prostate cancer cells [148].

In castration-resistant prostate cancer (CRPC), PF-03084014 (0.1–10 µM) treatment, with or without docetaxel, resulted in a greater decrease in the tumor growth of both docetaxel-resistant and docetaxel-sensitive CRPC compared with either compound alone. The results also showed that this treatment increased the anticancer activity and apoptosis, decreased the epithelial to mesenchymal transition, reduced survival signals (EGFR, cyclin E, NF-kB, and PI3K/Akt pathway; Bcl-xL; and Bcl-2), decreased the density of microvessels, and eliminated CSCs in the tumor [149].

Various studies, as presented in this review, have demonstrated the anti-CSC effect of GSIs. GSIs have different chemical structures, but despite these differences, all of them can inhibit Notch signaling, making them excellent candidates for potential anti-CSC agents. The anti-CSC effect of GSIs has been tested in various cancer cell lines and animal models. Various GSIs, with different concentrations, doses, and treatment durations, have been used in the reviewed studies. The elimination of CSCs using GSIs depends on the GSI type, cell line used, GSI concentration, and other anticancer agents used for combination treatment. In vitro anti-CSC activity and in vivo tumor growth inhibition accompanied by longer survival provides the proof of the efficacy of GSIs. All reviewed studies indicate consistency of their results and confirm Notch inhibition by using GSIs.

Probable mechanisms involved in observed anti-CSC effects of GSIs include apoptosis, cell cycle arrest, reduced survival signals (EGFR, cyclin E, NF-kB, and PI3K/Akt pathway; Bcl-xL; and Bcl-2), decreased protein levels of NICD1 mRNA, and protein expressions of Sox2 and Oct4 [135–139,144,145,148,149]. Most studies compared results obtained with GSIs in the presence and absence of other anticancer drugs. The results of these studies showed that GSIs in combination with other chemotherapeutic drugs have a greater inhibitory effect on CSCs. Additionally, GSIs increase the sensitivity of CSCs to anticancer drugs and enhance their anti-CSC effects [48–52,144–146].

The reviewed studies showed that increased concentrations of GSIs reduce the CSC growth rate and their anti-CSC effects are time- and concentration-dependent [36,54,104,122,134]. Higher concentrations of GSIs have a higher risk of toxicity. Therefore, a balance between toxicity and enhancement of the concentration should be set. One study showed that the combination of GSI with glucose-functionalized nanoparticles increased the anti-CSC effect and, at the same time, required a lower concentration to effectively reduce the CSCs in breast cancer [82]. If GSI-loaded nanoparticles are selectively localized in tumor cells, cancerous tissue can receive a higher dose in comparison to normal tissue. Therefore, the toxicity and side effects of GSI could be reduced.

6. Conclusions

There is evidence that CSCs induce tumor perpetuation, even after effective therapies, and result in aggression of the tumor. Given that Notch signaling is implicated in regulation of the cell fate, the aberrant activation of this pathway can lead to tumorigenesis. Therefore, the suppression of this pathway could be a potential therapeutic target for cancer management. This is the first study that provides a systematic review of the literature on the mechanisms of action of GSIs against various CSCs, although there are many other studies on the effect of GSIs on cancer cells rather than CSCs. Various studies have revealed that GSIs have potent anti-CSC effects and can inhibit the neoplastic activities, angiogenesis, and tumor growth of cancer cells, especially when combined with chemotherapeutic or targeted therapy drugs. Since Notch signaling has a critical role in the self-renewal and
maintenance of CSCs, GSIs have a greater effect on CSCs in comparison to cancer cells. Therefore, the eradication of CSCs by GSIs could lead to higher survival rates.

The potential ability of GSIs to target CSCs is mediated through the inhibition of various stemness-related signaling pathways and transcription factors. Of note, the importance of the other cellular events and signaling pathway interactions that contribute to tumor progression should be considered when it comes to designing a therapeutic plan that involves GSIs. Apart from their advantages, GSIs cause adverse severe side effects. For some GSIs, a high potency and optimal physical properties have been achieved, but the biological mechanism imposes inbuilt Notch-related side effects. Therefore, they are dose-limiting and need moderate, intermittent administration. Consequently, the effective inhibition of Notch pathway activity requires more targeted delivery approaches and the effective delivery of GSIs to CSCs to target Notch signaling in this population. One of the strategies for overcoming these challenges is using the specific properties of CSCs in the design of nanoparticles containing GSIs to improve the outcome of targeted treatment. Another strategy could be the use of small molecules, such as CB-103, which might target the Notch transcription complex to downregulate Notch signaling. In this systematic review, we conclude that inhibiting Notch signaling by GSIs is a promising strategy for achieving efficient cancer therapy.

Author Contributions: M.H.F. conceived and designed the study. M.G.-M. and Z.G.-M. collected and reviewed the literature and extracted and analyzed the data. M.G.-M. and Z.G.-M. prepared the first draft of the manuscript and created the figures. M.G.-M. and M.H.F. collected additional literature, refined mechanistic figures, edited the manuscript, and suggested improvements. S.M. and K.L.K. edited the manuscript. A.B. coordinated this project and reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Ayob, A.Z.; Ramasamy, T.S. Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 2018, 25, 1–18.
2. Lathia, J.D.; Liu, H. Overview of cancer stem cells and stemness for community oncologists. Target. Oncol. 2017, 12, 387–399. [CrossRef]
3. Akbarzadeh, M.; Maroufi, N.F.; Tazehkand, A.P.; Akbarzadeh, M.; Bastani, S.; Safdari, R.; Farzane, A.; Fattahi, A.; Nejabati, H.R.; Nouri, M. Current approaches in identification and isolation of cancer stem cells. J. Cell. Physiol. 2019, 234, 14759–14772. [CrossRef] [PubMed]
4. Kemper, K.; Sprick, M.R.; de Bree, M.; Scopelliti, A.; Vermeulen, L.; Hoek, M.; Zeilstra, J.; Pals, S.T.; Mehmet, H.; Stassi, G. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010, 70, 719–729. [CrossRef]
5. Weiswald, L.-B.; Bellet, D.; Dangles-Marie, V. Spherical cancer models in tumor biology. Neoplasia 2015, 17, 1–15.
6. Liu, J.; Sato, C.; Cerletti, M.; Wagers, A. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr. Top. Dev. Biol. 2010, 92, 367–409. [PubMed]
7. Venkatesh, V.; Nataraj, R.; Thangaraj, G.S.; Karthikeyan, M.; Gnanasekaran, A.; Kaginei, S.B.; Kappan, G.; Kallappa, C.G.; Basalingoppa, K.M. Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investig. 2018, 5. [CrossRef]
8. Rizzo, P.; Osipo, C.; Foreman, K.; Golde, T.; Osborne, B.; Miele, L. Rational targeting of Notch signaling in cancer. Oncogene 2008, 27, 5124–5131. [PubMed]
9. Curry, C.L.; Reed, L.L.; Golde, T.E.; Miele, L.; Nickoloff, B.J.; Foreman, K.E. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells. Oncogene 2005, 24, 6333–6344. [CrossRef] [PubMed]
10. Andersson, E.R.; Lendahl, U. Therapeutic modulation of Notch signalling—are we there yet? Nat. Rev. Drug Discov. 2014, 13, 357–378. [PubMed]
11. Orza, A.; Casciano, D.; Biris, A. Nanomaterials for targeted drug delivery to cancer stem cells. Drug Metab. Rev. 2014, 46, 191–206. [CrossRef]
12. Nie, P.; Vartak, A.; Li, Y.M. γ-Secretase inhibitors and modulators: Mechanistic insights into the function and regulation of γ-Secretase. Semin. Cell Dev. Biol. 2020, 105, 43–53. [CrossRef] [PubMed]
36. Gal, H.; Amariglio, N.; Trakhtenbrot, L.; Jacob-Hirsh, J.; Margalit, O.; Avigdor, A.; Nagler, A.; Tavor, S.; Ein-Dor, L.; Lapidot, T.; et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. *Leukemia* **2006**, *20*, 2147–2154. [CrossRef] [PubMed]

37. Tatarko, J.; Cullion, K.; Ashworth, T.; Gerstein, R.; Aster, J.C.; Kellieër, M.A. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. *Blood* **2011**, *118*, 1579–1590. [CrossRef] [PubMed]

38. Okuhashi, Y.; Itoh, M.; Nara, N.; Tohda, S. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. *Anticancer Res.* **2011**, *31*, 893–906.

39. Okuhashi, Y.; Itoh, M.; Arai, A.; Nara, N.; Tohda, S. γ-secretase inhibitors induce erythroid differentiation in erythroid leukemia cell lines. *Anticancer Res.* **2010**, *30*, 4071–4074.

40. Issa, M.E.; Berndt, S.; Carpentier, G.; Pezzuto, J.M.; Cuenod, M. Bruceantin inhibits multiple myeloma cancer stem cell proliferation. *Cancer Biol. Ther.* **2016**, *17*, 966–975. [CrossRef]

41. Hu, Y.Y.; Fu, L.A.; Li, S.Z.; Chen, Y.; Li, J.C.; Han, J.; Liang, L.; Li, L.; Ji, C.C.; Zheng, M.H.; et al. Hif-1α and Hif-2α differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells. *Cancer Lett.* **2014**, *314*, 67–76. [CrossRef]

42. Li, Y.; He, Z.C.; Zhang, X.N.; Liu, Q.; Chen, C.; Zhu, Z.; Chen, Q.; Shi, Y.; Yao, X.H.; Cui, Y.H.; et al. Stanniocalcin-1 augments proliferation of human glioma cell line SHG-44. *Asian Pac. J. Trop. Med.* **2011**, *4*, 552–556. [CrossRef]

43. Wang, Y.; Wang, Y.; Chen, H.; Hong, L.; Liu, N.; Fan, Q.; Lu, X.; et al. Increased Notch signaling enhances radioresistance of malignant stromal cells induced by glioma stem/progenitor cells. *PLoS ONE* **2015**, *10*, e0142594. [CrossRef] [PubMed]

44. Gal, H.; Makovitzki, A.; Amariglio, N.; Rechavi, G.; Ram, Z.; Givol, D. A rapid assay for drug sensitivity of glioblastoma stem cells. *Biochem. Biophys. Res. Commun.* **2007**, *12*, 1205–1219. [CrossRef] [PubMed]

45. Wang, Y.; Wang, Y.; Chen, H.; Liang, Q. Endothelial Cells Promote Formation of Medulloblastoma Stem-Like Cells via Notch Pathway Activation. *J. Mol. Neurosci.* **2017**, *63*, 152–158. [CrossRef]

46. Kanabur, P.; Guo, S.; Simonds, G.R.; Kelly, D.F.; Gourdie, R.G.; Verbridge, S.S.; Sheng, Z. Patient-derived glioblastoma stem cells respond differentially to targeted therapiess. *Oncotarget* **2016**, *7*, 86406–86419. [CrossRef]

47. Floyd, D.H.; Kefas, B.; Seleverstov, O.; Mykhaylyk, O.; Domínguez, C.; Comeau, L.; Plank, C.; Purow, B. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. *Neuro. Oncol.* **2012**, *14*, 1215–1226. [CrossRef] [PubMed]

48. Park, N.I.; Guilhamon, P.; Desai, K.; McAdam, R.F.; Langille, E.; O’Connor, M.; Lan, X.; Whetstone, H.; Coutinho, F.J.; Vanner, R.J.; et al. ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells. *Cell Stem Cell* **2019**, *21*, 209–224. [CrossRef] [PubMed]

49. Saito, N.; Hirai, N.; Aoki, K.; Suzuki, R.; Fujita, S.; Nakayama, H.; Hayashi, M.; Ito, K.; Sakurai, T.; Iwabuchi, S. The oncogene addiction switch from NOTCH to PI3K requires simultaneous targeting of NOTCH and PI3K pathway inhibition in glioblastoma. *Cancers (Basel)* **2019**, *11*, 121. [CrossRef] [PubMed]

50. Wang, J.; Wakeman, T.P.; Lathia, J.D.; Hjelmeland, A.B.; Wang, X.F.; White, R.R.; Rich, J.N.; Sullenger, B.A. Notch promotes radioresistance of glioma stem cells. *Stem Cells* **2010**, *28*, 17–28. [CrossRef]

51. Fan, X.; Khaki, L.; Zhu, T.S.; Soules, M.E.; Talsma, C.E.; Gul, N.; Koh, C.; Zhang, J.; Li, Y.M.; Maciacyk, J.; et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. *Stem Cells* **2010**, *28*, 5–16. [CrossRef] [PubMed]

52. Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.M.; Eberhart, C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. *Cancer Res.* **2006**, *66*, 7445–7452. [CrossRef]

53. Dai, L.; He, J.; Liu, Y.; Byun, J.; Vivekanandan, A.; Pennathur, S.; Fan, X.; Lubman, D.M. Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor. *Proteomics* **2011**, *11*, 4529–4540. [CrossRef]

54. Charles, N.; Ozawa, T.; Squatrito, M.; Bleau, A.M.; Brennan, C.W.; Hambardzumyan, D.; Holland, E.C. Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells. *Cell Stem Cell* **2010**, *6*, 141–152. [CrossRef] [PubMed]
60. Fornara, O.; Bartek, J.; Rahbar, A.; Odeberg, J.; Khan, Z.; Peredo, I.; Hamerlik, P.; Bartek, J.; Straglлотто, G.; Landázuri, N.; et al. Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: Prognostic significance and biological impact. *Cell Death Differ.* **2016**, *23*, 261–269. [CrossRef] [PubMed]

61. Tanaka, S.; Nakada, M.; Yamada, D.; Nakano, I.; Todo, T.; Ino, Y.; Hoshii, T.; Tadokoro, Y.; Ohta, K.; Ali, M.A.E.; et al. Strong therapeutic potential of γ-secretase inhibitor MKR003 for CD44-high and CD133-low glioblastoma initiating cells. *J. Neurooncol.* **2015**, *121*, 239–250. [CrossRef] [PubMed]

62. Natsume, M.; Maitani, K.; Liu, Y.; Miyahara, H.; Kaur, H.; Chu, Q.; Zhang, H.D.; Kahlert, U.; Eberhart, C.G. Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neuropheres. *Brain Pathol.* **2016**, *26*, 713–723. [CrossRef]

63. Lin, J.; Zhang, X.M.; Yang, J.C.; Ye, Y.B.; Luo, S.Q. γ-secretase inhibitor-I enhances radiosensitivity of glioblastoma cell lines by depleting CD133+ tumor cells. *Arch. Med. Res.* **2010**, *41*, 519–529. [CrossRef]

64. Ulasov, I.V.; Nandi, S.; Dey, M.; Sonabad, A.M.; Lesniak, M.S. Inhibition of sonic hedgehog and notch pathways enhances sensitivity of cd133+ glioma stem cells to temozolomide therapy. *Mol. Med.* **2011**, *17*, 103–112. [CrossRef] [PubMed]

65. Pietras, A.; Katz, A.M.; Ekström, E.J.; Wee, B.; Halliday, J.J.; Pitter, K.L.; Werbeck, J.L.; Amankulor, N.M.; Huse, J.T.; Holland, E.C. Osteopontin-CD44-mediated autophagy in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. *Cell Stem Cell* **2014**, *14*, 357–369. [CrossRef] [PubMed]

66. Ma, Y.; Cheng, Z.; Liu, J.; Torre-Healy, L.; Lathia, J.D.; Nakano, I.; Guo, Y.; Thompson, R.C.; Freeman, M.L.; Wang, J. Inhibition of notch1 activation in caveolae. *Neoplasia (U. S.)* **2015**, *17*, 497–508. [CrossRef] [PubMed]

67. Cho, Y.; Lee, H.W.; Kang, H.G.; Kim, H.Y.; Kim, S.J.; Chun, K.H. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. *Oncotarget* **2015**, *6*, 8709–8721. [CrossRef]

68. Li, W.; Yang, H.; Li, X.; Han, L.; Xu, N.; Shi, A. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer. *Oncol. Lett.* **2018**, *16*, 6095–6099. [CrossRef]

69. Hu, Y.; Cheng, G.; Li, L.; Liang, L.; Gao, F.; Wei, Y.N.; Fu, L.A.; Han, H. Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. *BMC Cancer* **2011**, *11*, 82. [CrossRef]

70. Hsu, E.C.; Kulp, S.K.; Huang, H.L.; Tu, H.J.; Salunke, S.B.; Sullivan, N.J.; Sun, D.; Wicha, M.S.; Shapiro, C.L.; Chen, C.S. Function of integrin-linked kinase in modulating the stemness of il-6-abundant breast cancer cells by regulating γ-secretase-mediated notch1 activation in caveolae. *Neoplasia (U. S.)* **2015**, *17*, 497–508. [CrossRef] [PubMed]

71. Chen, J.H.; Kuo, K.T.; Bamodu, O.A.; Lin, Y.C.; Yang, R.B.; Yeh, C.T.; Chao, T.Y. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition. *Exp. Cell Res.* **2018**, *370*, 444–453. [CrossRef]

72. Cho, Y.; Lee, H.W.; Kang, H.G.; Kim, H.Y.; Kim, S.J.; Chun, K.H. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. *Oncotarget* **2015**, *6*, 8709–8721. [CrossRef]

73. Li, W.; Yang, H.; Li, X.; Han, L.; Xu, N.; Shi, A. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer. *Oncol. Rep.* **2019**, *41*, 437–446. [CrossRef] [PubMed]

74. Tao, L.; Roberts, A.L.; Dunphy, K.A.; Bigelow, C.; Yan, H.; Jerry, D.J. Repression of mammary stem/progenitor cells by p53 is mediated by notch and separable from apoptotic stemness. *Stem Cells* **2011**, *29*, 119–127. [CrossRef] [PubMed]

75. McGowan, P.M.; Simedrea, C.; Ribot, E.J.; Foster, P.J.; Palmieri, D.; Steeg, P.S.; Allan, A.L.; Chambers, A.F. Notch1 inhibition alters the CD44 hi/CD24 lo population and reduces the formation of brain metastases from breast cancer. *Mol. Cancer Res.* **2011**, *9*, 834–844. [CrossRef] [PubMed]

76. Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S.K.; Liu, W.; Pandey, P.R.; Fukuda, K.; Hirota, S.; Sugai, T.; et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. *Oncogene* **2011**, *30*, 4075–4086. [CrossRef]

77. Boelen, M.C.; Wu, T.J.; Nabet, B.Y.; Xu, B.; Qiu, Y.; Yoon, T.; Azzam, D.J.; Twyman-Saint Victor, C.; Wiemann, B.Z.; Ishwaran, H.; et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. *Cell* **2014**, *159*, 499–513. [CrossRef]

78. Farnie, G.; Willan, P.M.; Clarke, R.B.; Bundred, N.J. Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status. *PLoS ONE* **2013**, *8*, e56840. [CrossRef]

79. Harrison, H.; Simões, B.M.; Rogerson, L.; Howell, S.J.; Landberg, G.; Clarke, R.B. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. *Breast Cancer Res.* **2013**, *15*, R21. [CrossRef] [PubMed]

80. Buckley, N.E.; Nie An Tsaior, C.B.; Blayney, J.K.; Oram, L.C.; Crawford, N.T.; D’Costa, Z.C.; Quinn, J.E.; Kennedy, R.D.; Harkin, D.P.; Mullan, P.B. BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. *Nucleic Acids Res.* **2013**, *41*, 8601–8614. [CrossRef] [PubMed]

81. Ray, A.; Vasudevan, S.; Sengupta, S. 6-shogaol inhibits breast cancer cells and stem cell-like spheroids by modulation of notch signaling pathway and induction of autophagic cell death. *PLoS ONE* **2015**, e0137614. [CrossRef]
82. Mamaeva, V.; Niemi, R.; Beck, M.; Özliseli, E.; Desai, D.; Landor, S.; Gronroos, T.; Kronqvist, P.; Pettersen, I.K.N.; McCormack, E. Inhibition of notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying γ-secretase inhibitors. *Mol. Ther.* 2016, 24, 926–936. [CrossRef]

83. Phillips, T.M.; Kim, K.; Vlasi, E.; McBride, W.H.; Pajonk, F. Effects of recombinant erythropoietin on breast cancer-initiating cells. *Neoplasia* 2007, 9, 1122–1129. [CrossRef]

84. Lagadec, C.; Vlasi, E.; Alhiyari, Y.; Phillips, T.M.; Bochkur Dratver, M.; Pajonk, F. Radiation-induced notch signaling in breast cancer stem cells. *Int. J. Radiat. Oncol. Biol. Phys.* 2013, 87, 609–618. [CrossRef]

85. Luo, M.; Shang, L.; Brooks, M.D.; Jiagge, E.; Zhu, Y.; Buschhaus, J.M.; Conley, S.; Fath, M.A.; Davis, A.; Gheordunescu, E.; et al. Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. *Cell Metab.* 2018, 28, 69–86. [CrossRef]

86. Shah, D.; Wyatt, D.; Baker, A.T.; Simms, P.; Peiffer, D.S.; Fernandez, M.; Rakha, E.; Green, A.; Filipovic, A.; Miele, L.; et al. Inhibition of her2 increases jagged1-dependent breast cancer stem cells: Role for membrane jagged1. *Clin. Cancer Res.* 2018, 24, 4566–4578. [CrossRef] [PubMed]

87. D’Angelo, R.C.; Ouzounova, M.; Davis, A.; Choi, D.; Tchuenkam, S.M.; Kim, G.; Luther, T.; Quraishi, A.A.; Senbabaoglu, Y.; Conley, S.J.; et al. Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell-like activity. *Mol. Cancer Ther.* 2015, 14, 779–787. [CrossRef] [PubMed]

88. Kondratyev, M.; Kreso, A.; Hallett, R.M.; Girgis-Gabardo, A.; Barcelon, M.E.; Ilieva, D.; Ware, C.; Majumder, P.K.; Hassell, J.A. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. *Oncogene* 2012, 31, 93–103. [CrossRef]

89. Xing, F.; Kobayashi, A.; Okuda, H.; Watabe, M.; Pai, S.K.; Pandey, P.R.; Hirota, S.; Wilber, A.; Mo, Y.Y.; Moore, B.E.; et al. Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. *EMBO Mol. Med.* 2013, 5, 384–396. [CrossRef] [PubMed]

90. McClements, L.; Yakkundi, A.; Papaspyropoulos, A.; Harrison, H.; Ablett, M.; Jithesh, P.V.; McKeen, H.D.; Bennett, R.; Donley, C.; Kisseniennig, A.; et al. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD4 pathway. *Clin. Cancer Res.* 2013, 19, 3881–3893. [CrossRef] [PubMed]

91. Harrison, H.; Farnie, G.; Howell, S.J.; Rock, R.E.; Stylianou, S.; Brennan, K.R.; Bundred, N.J.; Clarke, R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. *Cancer Res.* 2010, 70, 709–718. [CrossRef] [PubMed]

92. Bu, P.; Chen, K.Y.; Chen, J.H.; Wang, L.; Walters, J.; Shin, Y.J.; Goerger, J.P.; Sun, J.; Witherspoon, M.; Rakhilin, N.; et al. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer. *Mol. Oncol.* 2012, 6, 370–381. [CrossRef]
103. Hayakawa, Y.; Ariyama, H.; Stancikova, J.; Sakitani, K.; Asahara, S.; Renz, B.W.; Dubeykovskaya, Z.A.; Shibata, W.; Wang, H.; Westphalen, C.B.; et al. Msi1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche. *Cancer Cell* 2015, 28, 800–814. [CrossRef] [PubMed]

104. Barat, S.; Chen, X.; Bui, K.C.; Bozko, P.; Götze, J.; Christgen, M.; Krech, T.; Malek, N.P.; Plentz, R.R. Gamma-secretase inhibitor IX (GSI) impairs concomitant activation of notch and wnt-beta-catenin pathways in CD441 gastric cancer stem cells. *Stem Cells Transl. Med.* 2017, 6, 819–829. [CrossRef] [PubMed]

105. Li, L.C.; Wang, D.L.; Wu, Y.Z.; Nian, W.Q.; Wu, Z.J.; Li, Y.; Ma, H.W.; Shao, J.H. Gastric tumor-initiating CD44+ cells and epithelial-mesenchymal transition are inhibited by γ-secretase inhibitor DAPT. *Oncol. Lett.* 2015, 10, 3293–3299. [CrossRef] [PubMed]

106. Heng, K.J.; Wu, D.C.; Cheng, K.H.; Chen, L.T.; Hung, W.C. RECK Inhibits Stemness Gene Expression and Tumorigenicity of Gastric Cancer Cells by Suppressing ADAM-Mediated Notch1 Activation. *J. Cell. Physiol.* 2014, 229, 191–201. [CrossRef] [PubMed]

107. Kato, R.; Iwamuro, M.; Shiraha, H.; Horiguchi, S.; Tanaka, E.; Matsumoto, K.; Ohyma, A.; Sawahara, H.; Nagahara, T.; Uchida, D.; et al. Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties. *Oncol. Lett.* 2015, 10, 5426–5432. [CrossRef] [PubMed]

108. Chen, H.F.; Huang, C.H.; Liu, C.J.; Hung, J.J.; Hsu, C.C.; Teng, S.C.; Wu, K.J. Twist1 induces endothelial differentiation of tumour cells through the Jagged1-KLF4 axis. *Nat. Commun.* 2014, 5, 4697. [CrossRef] [PubMed]

109. Wang, Z.; Da Silva, T.G.; Jin, K.; Han, X.; Ranganathan, P.; Zhu, X.; Sanchez-Mejias, A.; Bai, F.; Li, B.; Fei, D.L.; et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. *Cancer Res.* 2014, 74, 6364–6374. [CrossRef] [PubMed]

110. Mendelson, J.; Song, S.; Li, Y.; Maru, D.M.; Mishra, B.; Davila, M.; Hofstetter, W.L.; Mishra, L. Dysfunctional transforming growth factor-β signaling with constitutively active notch signaling in Barrett’s esophageal adenocarcinoma. *Cancer 2011, 117, 3691–3702. [CrossRef] [PubMed]

111. Zhao, Z.L.; Zhang, L.; Huang, C.F.; Ma, S.R.; Bu, L.L.; Liu, J.F.; Yu, G.T.; Liu, B.; Gutkind, J.S.; Kulkarni, A.B.; et al. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. *Sci. Rep.* 2016, 6, 24704. [CrossRef] [PubMed]

112. Upadhyay, P.; Nair, S.; Kaur, E.; Aich, J.; Dani, P.; Sethunath, V.; Gardi, N.; Chandrani, P.; Godbole, M.; Sonawane, K.; et al. Notch path way activation is essential for maintenance of stem-like cells in early tongue cancer. *Oncotarget* 2016, 7, 50437–50449. [CrossRef] [PubMed]

113. Kawaguchi, K.; Honda, M.; Yamashita, T.; Shirasaki, T.; Nishikawa, M.; Nio, K.; Arai, K.; Sakai, Y.; Yamashita, T.; et al. Jagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer. *Am. J. Pathol.* 2016, 24, 3145–3154. [CrossRef] [PubMed]

114. Wu, C.X.; Xu, A.; Zhang, C.C.; Olson, P.; Chen, L.; Lee, T.K.; Cheung, T.T.; Lo, C.M.; Wang, X.Q. Notch inhibitor PF-03084014 inhibits hepatocellular carcinoma growth and metastasis via suppression of cancer stemness due to reduced activation of Notch1–Stat3. *Mol. Cancer Ther.* 2017, 16, 1531–1543. [CrossRef] [PubMed]

115. Cao, L.; Zhou, Y.; Zhai, B.; Liao, J.; Xu, W.; Zhang, R.; Li, J.; Zhang, Y.; Chen, L.; Qian, H.; et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatocellular carcinoma cell lines. *BMC Gastroenterol.* 2011, 11, 71. [CrossRef] [PubMed]

116. Yang, X.; Xia, W.; Chen, L.; Wu, C.X.; Zhang, C.C.; Olson, P.; Wang, X.Q. Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. *Oncotarget* 2018, 9, 34996–35007. [CrossRef] [PubMed]

117. Kwon, H.; Song, K.; Han, C.; Zhang, J.; Lu, L.; Chen, W.; Wu, T. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway. *Am. J. Pathol.* 2017. [CrossRef] [PubMed]

118. Kato, R.; Iwamuro, M.; Shiraha, H.; Horiguchi, S.; Tanaka, E.; Matsumoto, K.; Ohyma, A.; Sawahara, H.; Nagahara, T.; Uchida, D.; et al. Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties. *Oncol. Lett.* 2015, 10, 5426–5432. [CrossRef] [PubMed]

119. Zheng, Y.; de la Cruz, C.C.; Sayles, L.C.; Alleyne-Chin, C.; Vaka, D.; Knaak, T.D.; Bigos, M.; Xu, Y.; Hoang, C.D.; Shrager, J.B.; et al. A Rare Population of CD24+ITGB4+Notchhi Cells Drives Tumor Propagation in NSCLC and Requires Notch3 for Self-Renewal. *Oncotarget* 2017, 8, 3293–3299. [CrossRef] [PubMed]

120. Liu, J.; Zhao, Z.L.; Zhang, L.; Huang, C.F.; Ma, S.R.; Bu, L.L.; Liu, J.F.; Yu, G.T.; Liu, B.; Gutkind, J.S.; Kulkarni, A.B.; et al. Notch1–Stat3. *Sci. Rep.* 2016, 6, 24704. [CrossRef] [PubMed]

121. Upadhyay, P.; Nair, S.; Kaur, E.; Aich, J.; Dani, P.; Sethunath, V.; Gardi, N.; Chandrani, P.; Godbole, M.; Sonawane, K.; et al. Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer. *Oncotarget* 2016, 7, 50437–50449. [CrossRef] [PubMed]

122. Sullivan, J.P.; Spinola, M.; Dodge, M.; Raso, M.G.; Behrens, C.; Gao, B.; Schuster, K.; Shao, C.; Larsen, J.E.; Sullivan, L.A.; et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells and sensitizes to chemotherapy. *Biochem. Biophys. Res. Commun.* 2014, 444, 670–675. [CrossRef] [PubMed]

123. Mao, Z.; Liu, J.; Mao, Z.; Huang, J.; Xie, S.; Liu, T. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitise to chemotherapy. *Biochem. Biophys. Res. Commun.* 2014, 444, 670–675. [CrossRef] [PubMed]

124. Zhang, Y.; Xu, W.; Guo, H.; Zhang, Y.; He, Y.; Lee, S.H.; Song, X.; Li, X.; Guo, Y.; Zhao, Y.; et al. NOTCH1 signaling regulates self-renewal and platinum chemoresistance of cancer stem-like cells in human non-small cell lung cancer. *Cancer Res.* 2017, 77, 3082–3091. [CrossRef] [PubMed]
125. Hassan, K.A.; Wang, L.; Korkaya, H.; Chen, G.; Maillard, I.; Beer, D.G.; Kalemkerian, G.P.; Wicha, M.S. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 2013, 19, 1972–1980. [CrossRef]

126. Arasada, R.R.; Amann, J.M.; Rahman, M.A.; Huppert, S.S.; Carbone, D.P. EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res. 2014, 74, 5572–5584. [CrossRef] [PubMed]

127. Ali, S.A.; Justilien, V.; Jamieson, L.; Murray, N.R.; Fields, A.P. Protein Kinase C Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell 2016, 29, 367–378. [CrossRef]

128. Patenaude, A.; Woerther, S.; Umlandt, P.; Wong, F.; Ibrahim, R.; Kyle, A.; Unger, S.; Fuller, M.; Parker, J.; Minchinton, A.; et al. A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. Microvasc. Res. 2015, 101, 38–47. [CrossRef]

129. Kumar, D.; Kumar, S.; Gorain, M.; Tomar, D.; Patil, H.S.; Radharani, N.N.V.; Kumar, T.V.S.; Patil, T.V.; Thulasiram, H.V.; Kundu, G.C. Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis. J. Investig. Dermatol. 2016, 136, 2462–2474. [CrossRef]

130. Mukherjee, N.; Almeida, A.; Partyka, K.A.; Lu, Y.; Schwan, J.V.; Lambert, K.; Rogers, M.; Robinson, W.A.; Robinson, S.E.; Applegate, A.J.; et al. Combining a GSI and BCL-2 inhibitor to overcome melanoma’s resistance to current treatments. Oncotarget 2016, 7, 84594–84607. [CrossRef] [PubMed]

131. Lin, X.; Sun, B.; Zhu, D.; Zhao, X.; Sun, R.; Zhang, Y.; Zhang, D.; Dong, X.; Gu, Q.; Li, Y.; et al. Notch+ cancer stem-like cells promote the metastatic and invasive ability of melanoma. Cancer Sci. 2016, 107, 1079–1091. [CrossRef] [PubMed]

132. Yu, L.; Fan, Z.; Fang, S.; Yang, J.; Gao, T.; Simões, B.M.; Eyer, R.; Guo, W.; Clarke, R.B. Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling. Oncotarget 2016, 7, 33055–33068. [CrossRef] [PubMed]

133. Dai, G.; Deng, S.; Guo, W.; Yu, L.; Yang, J.; Zhou, S.; Gao, T. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma. Mol. Cytogenet. 2019, 58, 3–18. [CrossRef] [PubMed]

134. Vathipadiekal, V.; Saxena, D.; Mok, S.C.; Hauschka, P.V.; Ozbun, L.; Clarke, J.; Partridge, J.C.; Poole, B.B.; Cheng, K.H.; et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. USA 2012, 109, E2939–E2948. [CrossRef]

135. Abe, E.V.; Kim, E.J.; Wu, J.; Hyenes, M.; Bednar, F.; Proctor, E.; Wang, L.; Dziubinski, M.L.; Simeone, D.M. The notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. Cancer Res. 2013, 73, 4172–4180. [CrossRef] [PubMed]

136. Jiang, L.Y.; Zhang, X.L.; Du, P.; Zheng, J.H. γ-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin. J. Cancer Res. 2011, 23, 140–146. [CrossRef] [PubMed]

137. Li, H.; Zhang, W.; Niu, C.; Lin, C.; Wu, X.; Jhan, Y.; Li, Y.; Ye, L.; Dai, Y.; Ouyang, Y.; et al. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway. Int. J. Cancer 2019, 145, 1921–1934. [CrossRef] [PubMed]

138. Kang, M.; Jiang, B.; Xu, B.; Lu, W.; Guo, Q.; Xie, Q.; Zhang, B.; Dong, X.; Chen, D.; Wu, Y. Delta-like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett. 2013, 330, 11–21. [CrossRef] [PubMed]

139. Palagani, V.; El Khatib, M.; Kossatz, U.; Bozko, P.; Müller, M.R.; Manns, M.P.; Krech, T.; Malek, N.P.; Plentz, R.R. Protein Kinase C Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell 2016, 29, 367–378. [CrossRef]

140. Ali, S.A.; Justilien, V.; Jamieson, L.; Murray, N.R.; Fields, A.P. Protein Kinase C Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell 2016, 29, 367–378. [CrossRef]

141. Capodanno, Y.; Buishand, F.O.; Pang, L.Y.; Kirpensteijn, J.; Mol, J.A.; Argyle, D.J. Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. Endocr. Relat. Cancer 2018, 25, 131–144. [CrossRef]

142. Lee, J.Y.; Song, S.Y.; Park, J.Y. Notch pathway activation targets chemoresistant insulinoma cancer stem cells. Endocr. Relat. Cancer 2018, 25, 131–144. [CrossRef]

143. Bailey, J.M.; Alsina, J.; Rasheed, Z.A.; McAllister, F.M.; Fu, Y.Y.; Plentz, R.; Zhang, H.; Pasricha, P.J.; Bardeesy, N.; Matsu, W.; et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterol. 2014, 146, 245–256. [CrossRef] [PubMed]

144. Abel, E.V.; Kim, E.J.; Wu, J.; Hyenes, M.; Bednar, F.; Proctor, E.; Wang, L.; Dziubinski, M.L.; Simeone, D.M. The notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS ONE 2014, 9, e91983. [CrossRef] [PubMed]

145. Mizuma, M.; Rasheed, Z.A.; Yabuuchi, S.; Omura, N.; Campbell, N.R.; De Wilde, R.F.; De Oliveira, E.; Zhang, Q.; Puig, O.; Matsu, W.; et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol. Cancer Ther. 2012, 11, 1999–2009. [CrossRef]

146. Maitra, A.; et al. Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis. J. Investig. Dermatol. 2016, 136, 2462–2474. [CrossRef]

147. Wang, L.; Ning, J.; Wakimoto, H.; Wu, S.; Wu, C.L.; Humphrey, M.R.; Rabkin, S.D.; Martuza, R.L. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKMK120 Synergize to Promote Suppression of Pancreatic Cancer Stem-like Cells. Mol. Ther.—Oncolytics 2019, 13, 58–66. [CrossRef] [PubMed]
148. Carvalho, F.L.F.; Marchionni, L.; Gupta, A.; Kummangal, B.A.; Schaeffer, E.M.; Ross, A.E.; Berman, D.M. HES6 promotes prostate cancer aggressiveness independently of Notch signalling. *J. Cell. Mol. Med.* 2015, 19, 1624–1636. [CrossRef] [PubMed]

149. Cui, D.; Dai, J.; Keller, J.M.; Mizokami, A.; Xia, S.; Keller, E.T. Notch pathway inhibition using PF-03084014, a γ-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. *Clin. Cancer Res.* 2015, 21, 4619–4629. [CrossRef] [PubMed]